ASSOCIATE EDITOR: DAVID R. SIBLEY

The A3 Adenosine Receptor: History and Perspectives

Pier Andrea Borea, Katia Varani, Fabrizio Vincenzi, Pier Giovanni Baraldi, Mojgan Aghazadeh Tabrizi, Stefania Merighi, and Stefania Gessi

Department of Medical Sciences, Pharmacology Section (P.A.B., K.V., F.V., S.M., S.G.), and Department of Pharmaceutical Sciences, University of Ferrara, Italy (P.G.B., M.A.T.)

Abstract——By general consensus, the omnipresent purine nucleoside adenosine is considered a major regulator of local tissue function, especially when energy supply fails to meet cellular energy demand. Adenosine mediation involves activation of a family of four G protein–coupled adenosine receptors (ARs): A_1, A_{2A}, A_{2B}, and A_3. The A_3 adenosine receptor (A_3AR) is the only adenosine subtype to be overexpressed in inflammatory and cancer cells, thus making it a potential target for therapy. Originally isolated as an orphan receptor, A_3AR presented a twofold nature under different pathophysiologic conditions: it appeared to be protective/harmful under ischemic conditions, pro/anti-inflammatory, and pro/antitumoral depending on the systems investigated. Until recently, the greatest and most intriguing challenge has been to understand whether, and in which cases, selective A_3 agonists or antagonists would be the best choice. Today, the choice has been made and A_3AR agonists are now under clinical development for some disorders including rheumatoid arthritis, psoriasis, glaucoma, and hepatocellular carcinoma. More specifically, the interest and relevance of these new agents derives from clinical data demonstrating that A_3AR agonists are both effective and safe. Thus, it will become apparent in the present review that purine scientists do seem to be getting closer to their goal: the incorporation of adenosine ligands into drugs with the ability to save lives and improve human health.

Address correspondence to: Katia Varani, Department of Medical Sciences, Pharmacology Section, Via Fossato di Mortara, 17-19, 44121 Ferrara, Italy. E-mail: vrk@unife.it; or Stefania Merighi, Department of Medical Science, Pharmacology Section, Via Fossato di Mortara, 17-19, 44121 Ferrara, Italy. E-mail: mhs@unife.it
  dx.doi.org/10.1124/pr.113.008540.

I. Introduction

The purine nucleoside adenosine has been identified as a major local tissue function regulator, particularly when cellular energy supply fails to meet the demand. Given its ability to equalize energy intake to metabolic demand, in the 1980s it was reputed to be a "retaliatory metabolite" (Fredholm et al., 2011; Fredholm, 2014). Adenosine is omnipresent, it is released by nearly all cells and is generated in the extracellular space through ATP breakdown by a series of ectoenzymes, including apyrase (CD39) and 5′-nucleotidase (CD73) (Zimmermann, 2000). The latter dephosphorylates extracellular AMP to adenosine, thus regulating the step that limits its formation. Extracellularly, adenosine concentration equilibrium is maintained by reuptake mechanisms operated through the action of specific transporters. Then, inside the cell, it is phosphorylated to AMP by adenosine kinase or degraded to inosine by adenosine deaminase. Intracellularly, adenosine formation is dependent upon the hydrolysis of AMP by an intracellular 5-nucleotidase or by hydrolysis of S-adenosyl-homocysteine. It is estimated that the levels of adenosine in the interstitial fluid fall within the 30–300 nM range (Fredholm et al., 2001).

Adenosine concentrations increase under metabolically unfavorable conditions. Tissue hypoxia, for example, leads to enhanced breakdown of ATP and increased generation of adenosine. In addition to this route, the release of adenosine might be potentiated by hypoxia-dependent inhibition of the salvage enzyme, adenosine kinase, which rephosphorylates the nucleoside to AMP (Decking et al., 1997). As adenosine is unstable, its half-life limited by deamination or cellular reuptake, a hypoxia-induced increase typically affects only local adenosine receptor signaling. Adenosine most likely belongs to the group of autacoids because it is not released in a transmitter or hormone-like fashion.

Adenosine mediates its effects by activation of a family of four G protein–coupled receptors (GPCRs): the A₁, A₂A, A₂B, and A₃ adenosine receptors (ARs) (Ralevic and Burnstock, 1998). These receptors differ in 1) their affinity for adenosine, 2) the type of G proteins they recruit and, finally, 3) the downstream signaling pathways activated in the target cells. A₁ and A₃ARs inhibit the regulation of adenylyl cyclase (AC) activity, whereas activation of the A₂A and A₂BAR subtypes stimulates AC, which leads to increases in cAMP levels. Early pharmacologic evidence for the existence of ARs was provided by specific antagonism—exerted by methylxanthines, caffeine, and theophylline—of adenosine-induced effects in the heart and brain (Sattin and Rall, 1970).

ARs are widely distributed throughout the body and the fact they are present in basically all cells makes them an interesting target for pharmacologic intervention in many pathophysiologic conditions linked to increased adenosine levels. Development of AR agonists/antagonists would, therefore, seem opportune, but the challenge is to ensure they are devoid of side effects.

In particular, A₃AR is now recognized as a potential therapeutic target and biologic marker given its overexpression in inflammatory and cancer cells, compared with low levels found in healthy cells. Fortunately, recent developments in the field of AR agonists and antagonists have helped scientists design and develop safer, more specific lead and back-up candidates for clinical development (Gessi et al., 2011a). The agonists are now considered protective agents in some therapeutic areas and drug candidates in both preclinical and clinical studies. The goal of this review is to cover both the basic science and relevant therapeutic applications of A₃AR ligands and provide an authoritative account of the current status of the field.

II. The Discovery of the A₃ Adenosine Receptor

The existence of the A₃AR was hypothesized about 30 years ago in an attempt to characterize the type of ARs involved in the inhibitory action of adenosine at the frog

neuromuscular junction (Ribeiro and Sebastião, 1984). A distinct AR was claimed to exist in the brain that was coupled to Ca^{2+} metabolism (Ribeiro and Sebastião, 1986). However, this was not the same A_3AR finally cloned. Another milestone on the way to the definition of the A_3AR was found in antigen-stimulated RBL-2H3 cells (Ali et al., 1990). This receptor was not given a name, but subsequent work identified it as what we now know as the A_3AR. Therefore the receptor functionally coupled, via a G protein, to phospholipase C (PLC) and Ca^{2+} in a stimulatory manner was distinguished from the putative A_3AR, which inhibited Ca^{2+}-dependent responses in electrically excitable tissues independently of AC (Ribeiro and Sebastião, 1986).

Then, isolation of a cDNA clone encoding a novel putative GPCR from a rat testis cDNA library was reported. Although the ligand for this receptor was not identified, the authors understandably speculated that the receptor, designated tgpcr1, could play a role in male reproduction (Meyerhof et al., 1991). In 1992, several cDNA sequences from rat striatum encoding GPCRs were reported, one of which (designated R226) was identical to tgpcr1 (Zhou et al., 1992). On the basis of the transmembrane domain sequence homology with adenosine A_1 (58%) and $A_{2A}ARs$ (57%) and its particular ability to bind AR ligands, it was concluded that R226 encoded a novel AR designated as A_3AR (Fozard, 2010). The high expression of the receptor in the testis was confirmed, but, more importantly, low level mRNAs were also shown to be present in the lungs, kidneys, heart, and parts of the central nervous system (CNS), implying that A_3AR could have more widespread biologic significance than simply modulating testicular function. Therefore, A_3AR is the only AR subtype to be cloned before its pharmacologic identification.

III. Molecular Characterization of the A_3 Adenosine Receptor

Homologs of the rat striatal A_3AR have been cloned from sheep and humans, thus revealing large interspecies differences in A_3AR structure. For example, rat A_3AR presents only a 74% sequence homology with sheep and human A_3AR, whereas between sheep and humans, this homology is 85%; moreover equine A_3AR has also shown a high degree of sequence similarity with that of humans and sheep (Brandon et al., 2006). This is reflected in the very different pharmacologic profiles of the species homologs, especially in terms of antagonist binding, which has made characterization of this AR subtype difficult.

A_3AR has been mapped on human chromosome 1p21–p13 (Atkinson et al., 1997) and consists of 318 amino acid residues. It has been determined that the A_3AR gene contains two exons separated by a single intron of about 2.2 kb (Murrison et al., 1996). The upstream sequence does not contain a TATA-like motif, but it does have

a CCAAT sequence and consensus binding sites for SP1, NF-IL6, GATA1, and GATA3 transcription factors. Involvement of the latter in transcriptional control of this gene would be consistent with the receptor playing a role in immune function.

A_3AR is a GPCR characterized by its C-terminal portion, which faces the intracellular compartment and seven transmembrane spanning domains. This region presents multiple Ser and Thr residues that may serve as potential phosphorylation sites of importance for rapid receptor desensitization upon agonist application (Palmer and Stiles, 2000). Phosphorylation leads to a decreased number of receptors in the high-affinity state and decreased agonist potency to inhibit AC activity. In human astrocytoma and murine melanoma cells, a short agonist exposure time results in rapid A_3AR internalization and functional desensitization, whereas prolonged treatment with the A_3AR agonists induces receptor uncoupling with receptor downregulation (Trincavelli et al., 2002a; Madi et al., 2003). This event was suggested to be mediated by mitogen-activated protein kinases (MAPKs) responsible for a feedback mechanism that controls GPCR kinase activity and receptor phosphorylation in Chinese hamster ovary (CHO) cells transfected with A_3AR (Trincavelli et al., 2002b). An A_3AR desensitization mechanism has also been proposed in rat hippocampal slices during oxygen and glucose deprivation (Pugliese et al., 2007).

To gain an insight into the molecular characteristics of A_3AR ligand interaction, a thermodynamic analysis of A_3AR binding site has been addressed. This original approach has shown that agonist binding is always totally entropy driven, whereas antagonist binding is driven by both enthalpy and entropy (Merighi et al., 2002b). Interestingly, the similarity between the thermodynamic parameters of all ARs most likely reflects a common ligand receptor interaction mechanism for ARs (Borea et al., 2000). This may explain the difficulty in obtaining selective adenosine ligands. Therefore, the availability of thermodynamic data adds important information to the decision-making process in drug development (Gessi et al., 2008a).

IV. Medicinal Chemistry and Pharmacology of A_3 Adenosine Receptor Ligands

A. Agonists

Potent and selective A_3AR agonists stem from multiple substitutions of the parent nucleoside, adenosine (Fig. 1). The structural modifications implicate N^6-, C^2-, and 5′-substitutions combined with the modification of ribose moiety.

Prototypical A_3AR agonists, such as N^6-(3-iodobenzyl) adenosine-5′-N-methyluronamide (IB-MECA, CF101), derive from a combined modification of adenosine at the 5′- and at N^6-positions (Fig. 1) (Gallo-Rodriguez et al., 1994). In receptor binding studies, IB-MECA has

Fig. 1. Chemical structures of typical adenosine derivatives as A$_3$AR agonists.

displayed constant inhibitory binding (K_i) values of 51, 2900, and 1.8 nM for human (h) A$_1$, A$_{2A}$, and A$_3$ARs, respectively, being 28- and 1611-fold selective against A$_1$ and A$_{2A}$ ARs (Table 1). The introduction of small groups at the C2 position of IB-MECA generally increased both A$_3$AR affinity and selectivity, thus leading to the discovery of 2-chloro-N^6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide (Cl-IB-MECA, CF102), a potent A$_3$AR agonist with a K_i value of 1.4 nM at hA$_3$AR and with good selectivity for the other ARs (Fig. 1; Table 1) (Kim et al., 1994). On the basis of the bioisosteric rationale, the 4′-thio analogs of Cl-IB-MECA were synthesized as A$_3$AR ligands (Jeong et al., 2003). Among them, 2-chloro-N^6-(3-iodobenzyl)-5-N-methylcarbamoyl-4-thioadenosine (LJ529) displayed a K_i value of 0.38 nM at the hA$_3$AR (Fig. 1). LJ529 is reported to have a higher binding affinity to hA$_3$AR than Cl-IB-MECA (K_i = 0.38 versus 1.4 nM; Table 1) (Jeong et al., 2003).

Another class of analogs structurally related to the adenosine core consists of derivatives having 2-(ar)-alkynyl chains combined with various substituents at the 6-position. In particular, 2-phenylethynyl-N^6-methyladenosine (PEMADO) has shown hA$_3$AR affinity in

the low nanomolar range (K_i = 0.44 nM), with A$_1$/A$_3$ and A$_{2A}$/A$_3$ selectivity of about 74,000 and 94,000, respectively (Fig. 1; Table 1) (Volpini et al., 2002). The ability to inhibit forskolin-stimulated AC has been tested and all these derivatives have proved to be partial A$_3$AR agonists; their efficacy is not significantly modified by the introduction of small alkyl substituents in the N^6-position (Volpini et al., 2009). One compound in this series, 2-hexyn-1-yl-N^6-methyladenosine (HEMADO), has shown high affinity (K_i = 1.1 nM) and 300- and 1091-fold selectivity versus the A$_1$ and A$_{2A}$AR subtypes, respectively (Fig. 1; Table 1). The tritium-labeled form [^{3}H]HEMADO binds to hA$_3$AR with an affinity equilibrium binding constant (K_D) of 1.1 nM (Klotz et al., 2007). Efforts to identify A$_3$AR agonists that are both potent and selective have led to the discovery of 3′-amino analogs properly modified at the 5′- and N^6- positions. One of these, N^6-[2-(3-methylisoxazol-5-ylmethoxy)-5-chloro]benzyl-3′-amino-adenosine-5′-N-methylcarboxamide, coded CP608,039, binds to hA$_3$AR with a K_i of 5.8 nM and possesses over 1000- and 8000-fold selectivity versus hA$_1$ and hA$_{2A}$AR, respectively (Fig. 1; Table 1). Compound CP608,039 displays full agonist activity at

TABLE 1
Affinity and selectivity values of selected A_3AR agonists

Affinity values are derived from Fredholm et al., 2011, unless otherwise indicated.

A_3AR Agonists	A_1AR K_i	$A_{2A}AR$ K_i	$A_{2B}AR$ K_i	A_3AR K_i	A_1/A_3	A_{2A}/A_3
			nM			
IB-MECA (CF101)	51 (h)	2900 (h)	11,000 (h)	1.8 (h)	28	1611
Cl-IB-MECA (CF 102)	220 (h)	5360 (h)	>10,000 (h)	1.4 (h)	157	3829
	280 (r)	470 (r)	>10,000 (m)	0.33 (r)	848	1424
	35 (m)	≈10,000 (m)	N.D.	0.18 (m)	194	>55,000
LJ529	193 (h)[a]	223 (h)[a]	N.D.	0.38 (h)[a]	508	586
PEMADO	32,800 (h)	41,700 (h)	>30,000 (h)	0.44 (h)	74,545	94,773
HEMADO	330 (h)	1200 (h)	>30,000 (h)	1.10 (h)	300	1091
CP608,039	7300 (h)	>50,000 (h)	N.D.	5.8 (h)	1259	>8621
	1750 (rb)	N.D.	N.D.	83 (rb)	21	N.D.
MRS3558 (CF502)	260 (h)	2330 (h)	>10,000 (h)	0.29 (h)	897	8034
	105 (r)	1080 (r)	N.D.	1.0 (r)	105	1080
	15.8 (m)	10,400 (m)	N.D.	1.49 (m)	11	6980
MRS5151	14,900 (h)	≈10,000 (h)	N.D.	2.38 (h)	6261	>4200
	10,500 (m)	>10,000 (m)	N.D.	24.4 (m)	430	>410

h, human; m, mouse; r, rat; rb, rabbit; N.D., no data available.
[a]Values are derived from Baraldi et al., 2012.

the hA_3AR, inhibiting the isoproterenol-stimulated cAMP increase with an EC_{50} of 3.4 nM (DeNinno et al., 2003).

Other selective A_3AR agonists have been reported based on modification of the ribose ring. The analogs contain the (*N*)-methanocarba (bicyclo[3.1.0]hexane) ring system, a rigid ribose substitute lacking the ether oxygen (Tchilibon et al., 2005). In this series, 4-[6-(3-chlorobenzylamino)-2-chloro-9*H*-purin-9-yl]-2,3-dihydroxy-*N*-methylbicyclo[3.1.0]hexane-1-carboxamide (MRS3558, CF502) has the pharmacologic profile of a full agonist with subnanomolar affinity (K_i = 0.29 nM for the hA_3AR; Table 1) (Fig. 1). This compound shows an 897-fold selectivity versus the hA_1AR subtype, whereas it is greatly reduced (11-fold) in the mouse due to an increased tolerance of this ring system at A_1AR. As in the 2-alkynyl (*N*)-methanocarba derivative (MRS5151), the introduction of 2-alkynyl chains of varying lengths tends to increase A_3AR selectivity in the mouse (m) (up to 430-fold) and preserve it in humans (6261-fold) (Fig. 1; Table 1). Molecular modeling predicted that the sulfonate groups on C2-phenylethynyl substituents would provide high affinity at both m/hA_3AR, whereas a N^6-p-sulfophenylethyl substituent would determine higher hA_3AR versus mA_3AR affinity. N^6-3-Chlorobenzyl-2-(3-sulfophenylethynyl) derivative (MRS5841) binds selectively to human and mouse A_3ARs (K_i hA_3AR = 1.9 nM) as an agonist, whereas the corresponding *p*-sulfo isomer (MRS5701) displays mixed A_1/A_3AR agonism (Paoletta et al., 2013).

In this context, different chemically functionalized alkynyl chains (esters, amino groups, or carboxylic acid) potentially useful for making conjugates as receptor probes have been synthesized (Melman et al., 2008). Recently, macromolecular conjugates [e.g., polyamidoamine (PAMAM) dendrimers], a particularly versatile and biocompatible class of polymeric drug carriers of chemically functionalized agonists, have been synthesized as potent polyvalent activators of A_3AR (Tosh et al., 2010).

B. Antagonists

In an initial attempt, a large number of heterocyclic compounds were synthesized and evaluated as A_3AR antagonists (Jacobson et al., 1995; Siddiqi et al., 1995; Ji et al., 1996). In particular a triazoloquinazoline derivative 9-chloro-2-(2-furanyl)-5-[(phenylacetyl)amino][1,2,4]-triazolo[1,5-*c*]quinazoline (MRS1220) was developed as a very potent compound at the hA_3AR, with K_i of 0.59 nM (Fig. 2; Table 2) (Kim et al., 1996).

Several xanthine or purine analogs were examined first, but none showed significant affinity or selectivity to rat (r) A_3AR (Jacobson et al., 2009).

An approach to designing dihydropyridines that bind to ARs without binding to L-type calcium channels has been described. For example, a trisubstituted 1,4-dihydro-6-phenylpyridine analog 3-ethyl-5-benzyl-2-methyl-4-phenylethynyl-6-phenyl-1,4-dihydropyridine-3,5-dicarboxylate (MRS1191), has been found to inhibit radioligand binding at the hA_3AR with a K_i value of 31.4 nM (Fig. 2; Table 2), whereas the same derivative is nearly inactive in binding at A_1 and $A_{2A}ARs$ (Jacobson et al., 1997). One of the first heterocyclic, selective, and competitive A_3AR antagonists was 3-propyl-6-ethyl-5[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine-carboxylate (MRS1523), a pyridine derivative that acts as a highly selective antagonist of A_3AR with good potency in both humans and rodents, with K_i values of 18.9 nM for hA_3AR and 113 nM for rA_3AR (Fig. 2; Table 2) (Li et al., 1998). MRS1523 exhibits only a weaker antagonistic activity toward A_1 and $A_{2A}ARs$ (K_i = 15.6 and 2.05 μM for rA_1 and $A_{2A}ARs$, respectively) (Li et al., 1998).

Another class of analogs, structurally related to isoquinoline and quinazoline urea derivatives, was found as adenosine A_3AR antagonists. The combination of the optimal substituents in the two series led to the potent hA_3AR antagonist *N*-(2-methoxyphenyl)-*N'*-(2-(3-pyridyl)quinazolin-4-yl)urea VUF-5574, with a K_i value of 4.03 nM and over 2400-fold selectivity versus A_1

Fig. 2. Chemical structures of typical A$_3$AR antagonists.

and A$_{2A}$ARs (Fig. 2; Table 2). In an in vitro functional assay, the compound competitively antagonized the inhibition of cAMP production induced by N^6-ethyl-carboxamidoadenosine in CHO cells expressing hA$_3$AR with a pA_2 value of 8.1 (van Muijlwijk-Koezen et al., 2000).

The first example of an AR antagonist containing the pyrazolo-triazolo-pyrimidine scaffold was reported in 1993 (Gatta et al., 1993). Intensive efforts in the chemical synthesis of compounds based on the systematic substitution at the C^2-, C^5-, C^9-, N-^{7}, and N^8-positions of the tricyclic template led to the MRE series (Baraldi et al., 1999, 2000, 2002, 2003). This innovative series of compounds includes N-[2-(2-furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-yl]-N'-

(4-methoxyphenyl)urea (MRE 3008F20) an antagonist with high affinity at hA$_3$AR (K_i = 0.82 nM; Table 2) and high selectivity (1463- and 172-fold) over human A$_1$ and A$_{2A}$ARs, respectively (Fig. 2) (Varani et al., 2000). In a functional assay MRE 3008F20 showed antagonist activity capable of blocking the effect of IB-MECA on cAMP production in CHO cells (IC$_{50}$ = 4.5 nM). The tritium-labeled compound was able to bind the hA$_3$AR expressed in CHO cells with a K_D value of 0.82 nM and a B_{max} value of 297 fmol/mg protein (Varani et al., 2000). The isosteric replacement of the phenyl with a 4-pyridyl moiety led to the water-soluble hA$_3$AR antagonist ^5N(4-methoxyphenylcarbamoyl)amino-8-phenylethyl-2-(2-furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine (MRE 3005F20) with subnanomolar affinity

TABLE 2
Affinity and selectivity values of selected A₃AR antagonists

Affinity values are derived from Fredholm et al., 2011, unless otherwise indicated.

A₃AR Antagonists	A₁AR K_i	A₂ₐAR K_i	A₂ᵦAR K_i	A₃AR K_i	A₁/A₃	A₂ₐ/A₃
			nM			
MRS1220	231[a]	25[a]	N.D.	0.59[a]	391	42
MRS1191	>10,000 (h)	>10,000 (h)	>10,000 (h)	31.4 (h)	>318	>318
	40,100 (r)	>10,000 (r)		1850 (r)	22	>5
MRS1523	>10,000 (h)	3660 (h)	>10,000 (h)	18.9 (h)	>529	194
	15,600 (r)	2050 (r)		113 (r)	138	18
	N.D.	N.D.	>10,000 (m)	731 (m)	N.D.	N.D.
VUF-5574	>10,000 (r)	>10,000 (r)	N.D.	4.03 (h)	>2481	>2481
MRE 3008F20	1200 (h)	141 (h)	2100 (h)	0.82 (h)	1463	172
MRE 3005F20	350 (h)	100 (h)	250 (h)	0.01 (h)	35,000	10,000
OT-7999	>10,000 (h)[a]	>10,000 (h)[a]	N.D.	0.95 (h)[a]	>10,526	>10,526
PSB-10	1700 (h)	2700 (h)	N.D.	0.44 (h)	3864	6136
PSB-11	1640 (h)	1280 (h)	2100 (m)	2.34 (h)	701	547
KF26777	1800 (h)	470 (h)	620 (h)	0.20 (h)	9000	2350
Structure A	>10,000 (h)[b]	7490 (h)[b]	N.D.	4.90 (h)[b]	2041	1529
				231 (r)[b]		

h, human; m, mouse; r, rat; N.D., no data available.
[a]Values are derived from Baraldi et al., 2012.
[b]Nayak et al., 2014.

versus hA₃AR (K_i = 0.01 nM) and high selectivity (35,000- and 10,000-fold versus A₁ and A₂ₐARs, respectively), suggesting it as an ideal candidate for the pharmacologic and clinical investigation of the hA₃AR subtype (Fig. 2; Table 2) (Maconi et al., 2002).

The synthesis of 1,2,4-triazolo[5,1-*i*]purine derivatives by the modified method of pyrazolo[4,3-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidines has been reported as showing high affinity and selectivity for the hA₃AR, such as the 5-*n*-butyl-8-(4-trifluoromethylphenyl)-3*H*-[1,2,4]triazolo-[5,1-*i*]purine compound (OT-7999) (Fig. 2). In receptor binding assays, OT-7999 displayed high affinity for the hA₃AR (K_i = 0.95 nM) and >10,526-fold selectivity relative to other AR subtypes (Table 2). The ring annelation of xanthine derivatives for the development of AR antagonists has been investigated in depth (Okamura et al., 2002). The pyrido[2,1-*f*]purine-2,4-diones, which could be considered tricyclic xanthine derivatives, have been reported to exert subnanomolar affinity to hA₃AR (Drabczyńska et al., 2003). An important innovation of such a series, compared with xanthines, is the significant increase in water solubility, achieved by introducing a basic nitrogen atom, which could be protonated under physiologic conditions.

The imidazopurinone ring-enlarged 8(*R*)-ethyl-4-methyl-2-(2,3,5-trichlorophenyl)-4,5,7,8-tetrahydro-1*H*-imidazo[2,1-*i*]purin-5-one (PSB-10) has shown high affinity for hA₃ARs (K_i = 0.44 nM) with high selectivity over A₁ and A₂ₐARs (3864- and 6136-fold, respectively; Fig. 2; Table 2) (Muller et al., 2002). PSB-10 has demonstrated inverse agonist activity in binding studies in CHO cells expressing recombinant hA₃AR (IC₅₀ = 4 nM). Another similar compound of this series is 8(*R*)-ethyl-7,8-dihydro-4-methyl-2-phenyl-1*H*-imidazo[1,2-*g*]purin-5-one (PSB-11), exhibiting a K_i value of 2.34 nM for the hA₃AR and good selectivity versus all other AR subtypes (Ozola et al., 2003) (Fig. 2; Table 2).

The 2-(4-bromophenyl)-7,8-dihydro-4-propyl-1*H*-imidazo[2,1-*i*]purin-5(4*H*)-one derivative KF26777 has revealed subnanomolar affinity to hA₃AR (K_i 0.20 nM) and high selectivity over A₁ and A₂ₐ subtypes (9000- and 2350-fold, respectively) (Fig. 2; Table 2). It inhibits Cl-IB-MECA-induced [³⁵S]guanosine-5′-*O*-(3-thiotriphosphate) binding to human embryonic kidney 293 cells (IC₅₀ = 270 nM) and enhances intracellular Ca²⁺ concentrations in human promyelocytic cells (Saki et al., 2002).

Interestingly, the 5-(2-fluoroethyl) 2,4-diethyl-3-(ethylsulfanylcarbonyl)-6-phenylpyridine-5-carboxylate compound was presented as a ligand with high affinity, able to serve as the first positron emission tomography tracer for the A₃AR (Wadsak et al., 2008).

Moreover, a very recent study has obtained a novel series of A₃AR partial agonists and antagonists as truncated 2-hexynyl-N^6-substituted-(*N*)-methanocarba nucleosides, with K_i values of 7.8−16.0 nM (Nayak et al., 2014). These compounds were screened for renoprotective effects in a human kidney fibrosis model. Most compounds exhibited antifibrotic effects, with (1*R*,2*R*,3*S*,4*R*,5*S*)-4-(2-(hex-1-ynyl)-6-(methylamino)-9*H*-purin-9-bicyclo[3.1.0]hexane-2,3-diol (Structure A) being the most potent, indicating its potential as a good therapeutic candidate for treating renal fibrosis (Fig. 2; Table 2).

V. Distribution of the A₃ Adenosine Receptor

The generation of cDNA for A₃AR has made the identification of the tissue distribution of this receptor subtype possible. A₃AR is widely expressed, its mRNA being revealed in the testis, lung, kidneys, placenta, heart, brain, spleen, liver, uterus, bladder, jejunum, proximal colon, and eye of rats, sheep, and humans (Zhou et al., 1992; Salvatore et al., 1993; Linden, 1994;

Rivkees, 1994; Dixon et al., 1996; Burnett et al., 2010). However, marked differences in expression levels do exist within and between species. In particular, rat testis and mast cells express high concentrations of A$_3$ mRNA, whereas low levels have been detected in most other rat tissues (Linden et al., 1993; Salvatore et al., 1993). Human lung and liver are the organs that express high amounts of A$_3$ mRNA, whereas levels in the aorta and brain have been found to be low (Salvatore et al., 1993). The lung, spleen, pars tuberalis, and pineal gland express the highest concentrations of A$_3$ mRNA in sheep.

The presence of the A$_3$AR protein has been evaluated through radioligand binding, immuno- or functional assays in a variety of primary cells, tissues (Table 3), and cell lines (Table 4). In the brains of mouse, rat, gerbil, and rabbit, a widespread, relatively low level of A$_3$AR binding sites has been found (Jacobson et al., 1993; Ji et al., 1994). Owing to this very low expression, other authors have reported the impossibility of detecting either the A$_3$AR gene or binding site in the CNS from in situ hybridization experiments (Rivkees et al., 2000), and others have described A$_3$AR expression in the thalamus and hypothalamus (Yaar et al., 2002). However, electrophysiologic and biochemical evidence suggests the presence of A$_3$AR in the rat hippocampus (Dunwiddie et al., 1997; Macek et al., 1998; Lopes et al., 2003) and cortex (Brand et al., 2001); functional studies have also indicated its presence in the brain and retinal ganglion cells (Jacobson et al., 1993; von Lubitz et al., 1994; Haskó et al., 2005; Zhang et al., 2006a, 2010). The proposed presence of A$_3$AR at motor nerve terminals (Ribeiro and Sebastião 1986) was recently demonstrated through pharmacologic and immunohistochemical studies (Cinalli et al., 2013). At cellular level, A$_3$AR expression has been observed in microglia and astrocytes, the resident immune cells of the CNS (Hammarberg et al., 2003; Björklund et al., 2008a,b; van der Putten et al., 2009; Ohsawa et al., 2012; Gessi et al., 2013). Overall these data iron out the controversy as to whether A$_3$AR are in fact in the CNS.

In cardiomyocytes no direct evidence of the presence of A$_3$AR has been found (Peart and Headrick, 2007); however, a plethora of studies has reported it as being responsible for cardioprotection in a variety of species and models, including isolated cardiomyocytes and isolated myocardial muscle preparations (Tracey et al., 1997; Shneyvays et al., 1998, 2001; Thourani et al., 1999a,b; Cross et al., 2002; Harrison et al., 2002; Germack and Dickenson, 2004; Headrick and Peart, 2005; Xu et al., 2006). High A$_3$AR expression has been revealed in the human coronary and carotid artery (Hinze et al., 2012; Grandoch et al., 2013).

In enteric neurons and epithelial cells, the A$_3$AR was first evidenced by immunohistochemical studies (Christofi et al., 2001; Antonioli et al., 2010; Ren et al., 2011) and subsequently quantified in colonic mucosa by radioligand binding experiments (Gessi et al., 2004a). The presence of functional A$_3$AR has also been demonstrated in human lung parenchyma, in lung type 2 alveolar-like cells (A549), and in bronchi through radioligand binding and immunohistochemical assays (Varani et al., 2006; Calzetta et al., 2011).

It is worth noting that A$_3$AR has been revealed in a variety of primary cells involved in inflammatory responses. In rat basophilic leukemia cells (RBL-2H3), binding experiments have detected a high A$_3$AR density (Ramkumar et al., 1993; Olah et al., 1994) and different studies have reported that A$_3$AR plays a role in rat mast cell degranulation (Carruthers and Fozard, 1993; Fozard and Carruthers, 1993; Ramkumar et al., 1993; Hannon et al., 1995; el-Hashim et al., 1996; Fozard et al., 1996; Hua et al., 2008; Gomez et al., 2011). Recently, A$_3$AR stimulating degranulation has been demonstrated also in LAD2 bone marrow-derived human mast cells (Leung et al., 2014). Human eosinophils were the first cells in which native hA$_3$AR was detected by using radioligand binding (Kohno et al., 1996a; Morschl et al., 2008), and this was then followed by human neutrophils (Bouma et al., 1997; Gessi et al., 2002; Chen et al., 2006; van der Hoeven et al., 2008; Corriden et al., 2013; Mulloy et al., 2013), monocytes (Broussas et al., 1999, 2002; Thiele et al., 2004), macrophages (McWhinney et al., 1996; Szabo et al., 1998; Gessi et al., 2010a), foam cells (Gessi et al., 2010a), dendritic cells (Panther et al., 2001; Fossetta et al., 2003; Dickenson et al., 2003; Hofer et al., 2003), lymphocytes (Gessi et al., 2004b; Varani et al., 2009, 2010b), splenocytes, bone marrow cells, lymphonodes (Bar-Yehuda et al., 2011), and synoviocytes (Varani et al., 2008, 2010c; Stamp et al., 2012). Human chondrocytes and osteoblasts, two key cell types in the skeletal system, were recently found to express A$_3$AR (Vincenzi et al., 2013).

Finally, very high A$_3$AR protein expression was observed in a variety of cancer cell lines (Gessi et al., 2001, 2007, 2010b; Merighi et al., 2001, 2009; Suh et al., 2001; Morello et al., 2009; Jajoo et al., 2009; Cohen et al., 2011; Hofer et al., 2011; Varani et al., 2011a, 2013; Kanno et al., 2012; Nogi et al., 2012; Kamiya et al., 2012; Otsuki et al., 2012; Vincenzi et al., 2012; Nagaya et al., 2013; Sakowicz-Burkiewicz et al., 2013; Madi et al., 2013) and in cancer tissues (Gessi et al., 2004a; Madi et al., 2004; Bar-Yehuda et al., 2008; Varani et al., 2011a), thus suggesting a role for this subtype as a tumoral marker.

VI. Intracellular Pathways Regulated by the A$_3$ Adenosine Receptor

A$_3$ARs have been shown to couple to classic or G protein–dependent second messenger pathways through activation of both G$_i$ and G$_q$ family G proteins (Palmer et al., 1995; Merighi et al., 2003; Haskò and

TABLE 3
Distribution and effects of A$_3$ARs in primary tissue/cells

Primary Tissue/Cells	Species	Effects	References
Cerebellum	Mouse	Locomotor depression	Jacobson et al., 1993
Brain	Rat		Ji et al., 1994
Forebrain	Gerbil	Neuroprotection	Von Lubitz et al., 2001
Cerebellar granule neurons	Rat	Neurotoxicity	Sei et al., 1997
Cortical neurons	Rat	No effect on neuronal death	Rebola et al., 2005
Hippocampus	Rat		Lopes et al., 2003
Microglial cells	Rat	↑ Migration	van der Putten et al., 2009; Ohsawa et al., 2012
Astrocytes	Mouse	Protection ↓ LPS-induced HIF-1α level	Björklund et al., 2008b; Gessi et al., 2013
Pial and intracerebral arteries	Rat		Di Tullio et al., 2004
Neuromuscular junction	Mouse	Presynaptic inhibition of spontaneous and evoked ACh release	Cinalli et al., 2013
Cardiac myocytes	Rat	Ca^{2+} increase, apoptosis ↓ doxorubicin-induced cardiotoxicity. Protection from the loss of mitochondrial membrane potential	Shneyvays et al., 1998, 2001, 2005
Cardiac myocytes	Rabbit	Cardioprotection	Liu et al., 1994; Tracey et al., 1997
Heart	Mouse	Cardioprotection	Cross et al., 2002
Coronary artery smooth muscle cells	Human	↑ Proliferation	Hinze et al., 2012; Grandoch et al., 2013
Carotid artery		↑ Hyaluronan	
Mesenteric artery	Mouse	Vasodilation	Teng et al., 2013
Endothelial progenitor cells	Human	↑ Migration	Fernandez et al., 2012
Eosinophils	Human	Apoptosis, Ca^{2+} increase	Kohno et al., 1996a; Reeves et al., 2000; Morschl et al., 2008
Lymphocytes	Human	↓ cAMP ↓ NF-κB, IL-6, TNF-α, IL-1β ↓ MMP-1,MMP-3	Gessi et al., 2004a,b Varani et al., 2009, 2011b
White blood cells	Mouse	↑ Cell growth	Bar-Yehuda et al., 2002
Monocytes	Human	↓ NADPH oxidase ↓ Reactive oxygen intermediates	Broussas et al., 1999; Thiele et al., 2004
Macrophages	Human	↑ MMP-9	Velot et al., 2008
Neutrophils	Human	↓ Degranulation	Bouma et al., 1997; Gessi et al., 2002; Chen et al., 2006 ; van der Hoeven et al., 2008; Mulloy et al., 2013; Corriden et al., 2013
		↓ cAMP, Ca^{2+} increase ↓ Superoxide anion ↓ Chemotaxis and activation ↑ Chemotaxis ↑ Bacterial phagocytosis	
Dendritic cells	Human	Ca^{2+} increase	Panther et al., 2001; Fossetta et al., 2003
Healthy colon	Human		Gessi et al., 2004a
Retinal ganglion cells	Rat	Neuroprotection	Zhang et al., 2006a, 2010
Cytotoxic T cells	Mouse	↓ Proliferation	Hoskin et al., 2002
PBMC	Human	Induction of cell death Upregulation of A$_3$AR by NF-κB	Barbieri et al., 1998; Madi et al., 2007
Ciliary epithelial cells	Human	Regulation of Cl$^-$ channels	Mitchell et al., 1999; Schlotzer-Schrehardt et al., 2005.
Mast cells	Rat, guinea pig	Degranulation	Fozard et al., 1996; Koda et al., 2010
Mast cells	Mouse	Hyperresponsiveness Histamine release Ca^{2+} increase	Hua et al., 2008; Zhong et al., 2003
Lung parenchima	Human	↓ IL-1β	Varani et al., 2006
Pleural Mesothelioma	Human	↓ Cell growth, apoptosis, TNF-α	Varani et al., 2011a
Splenocytes, bone marrow cells, lymphonodes	Mouse	G-CSF production, Myelostimulation, ↓ PI3K, STAT-1	Bar-Yehuda et al., 2002
Chondrocytes	Bovine	↓ IL-8, PGE2	Varani et al., 2008; De Mattei et al., 2009
Synovial fibroblasts	Bovine	↓ IL-8, PGE2	Varani et al., 2008; De Mattei et al., 2009
Synovial fibroblasts	Human	↓ IL-8, TNF-α, PGE2, NF-κB, p38 MAPKs	Varani et al., 2010c; Ongaro et al., 2012; Stamp et al., 2012
Skeletal muscle	Mouse	↓ MMP-3, MMP-9	Urso et al., 2012
Liver	Mouse	↓ Apoptosis	Cohen et al., 2011
Testis	Human		Burnett et al., 2010
Trophoblast	Human	↑ MMP-2, MMP-9	Kim et al., 2008b
Chorionic villi	Human		Gessi et al., 2012

G-CSF, granulocyte colony-stimulating factor.

TABLE 4
Distribution and effects of A$_3$ARs in cell lines

Cell Lines	Species	Effects	References
RAW 264.7 macrophages	Mouse	↓ TNF-α, ↓ MIP-1α	Szabò et al., 1998; Martin et al., 2006
RBL-2H3 mast cells	Rat	↑ IP$_3$ and Ca^{2+}	Ramkumar et al., 1993; Olah et al., 1994
		↑ Release of allergic mediators	
HL60 promyelocytic	Human	Induction of cell death, ↓ cAMP, Ca^{2+} increase	Kohno et al., 1996b, Gessi et al., 2002
			Hofer et al., 2011
U937 macrophages	Human	↓ TNF-α, Induction of cell death	Sajjadi et al., 1996; Yao et al., 1997
J774.1 macrophages	Mouse	↓ TNF-α	McWhinney et al., 1996
ADF astrocytoma	Human	Changes in cytoskeleton, Bcl-X$_L$, Rho. ↓ cAMP, internalization, desensitization	Abbracchio et al., 1997, 2001; Trincavelli et al., 2002a
D384 astrocytoma	Human	↓ Apoptosis	Björklund et al., 2008b
Jurkat lymphoma	Human	↓ cAMP, Ca^{2+} increase	Gessi et al., 2001
A375 melanoma	Human	↓ cAMP, Ca^{2+} increase	Merighi et al., 2001, 2005a,b, 2009
		↑ HIF-1α ↓ proliferation	
PGT-β pineal gland	Mouse	↓ cAMP	Suh et al., 2001
XS-106 dendritic	Mouse	↓ TNF-α	Dickenson et al., 2003
HT29, Caco2, DLD1 colon	Human	↓ cAMP, Ca^{2+} increase,	Gessi et al., 2007; Merighi et al., 2007b; Sakowicz-Burkiewicz et al., 2013
		↑ Cell proliferation	
		↑ HIF-1α and VEGF	
HCT116 colon	Human	↓ Proliferation	Sakowicz-Burkiewicz et al., 2013
BV2 microglia	Mouse	↓ TNF-α/PI 3-kinase/ NF-κB	Hammarberg et al., 2003 ; Lee et al., 2006a
B-16-F10 melanoma	Rat	↓ Tumor cells growth	Fishman et al., 2002b; Madi et al., 2003, 2013
		Desensitization	
		↑ Melanin	
Nb2-11C lymphoma	Rat	↓ Proliferation	Fishman et al., 2000
PC-3 prostate	Human	↓ Proliferation	Fishman et al., 2003
		↑ Apoptosis	Aghaei et al., 2011
LN Cap prostate	Human	↓ Proliferation	Fishman et al., 2002b
AT6.1 prostate	Rat	↓ Cancer invasiveness	Jajoo et al., 2009
MiaPaCa pancreas	Human	↓ Proliferation	Fishman et al., 2002b
MCA sarcoma	Mouse	↓ Proliferation	Fishman et al., 2002b
Li-7A hepatoma	Human	↑ Apoptosis	Wen and Knowles, 2003
N1S1 hepatoma	Rat	↑ Apoptosis	Bar-Yehuda et al., 2008
Hep-3B hepatoma	Human	↑ Apoptosis	Cohen et al., 2011
Thyroid cancer	Human	↑ Apoptosis	Morello et al., 2009
MCF-7, MDA-MB468 breast	Human	↓ Tumor cells growth	Panjehpour and Karami-Tehrani, 2004
MRMT-1 breast	Rat	↓ Tumor cells growth	Varani et al., 2013
U87MG, A172 glioblastoma	Human	↑ Hypoxic cell survival	Merighi et al., 2007a; Gessi et al., 2010b
		↑ MMP-9	
PC12	Rat	↓ Proliferation	Vincenzi et al., 2012
2H3 basophilic leukemia mast cells	Rat	↓ Apoptosis	Gao et al., 2001
LAD2 mast cells	Human	↑ Degranulation	Leung et al., 2014
A6 renal	Toad	↑ Ca^{2+} influx,	Reshkin et al., 2000
		↑ Chloride secretion	
NRK-52E renal tubular epithelial cell line	Rat	↑ Apoptosis	Kadomatsu et al., 2012
A549 lung type 2 alveolar-like	Human	↑ Apoptosis	Varani et al., 2006; Kamiya et al.,2012
SBC3 lung	Human	↑ Apoptosis	Kanno et al., 2012
Lu65 lung			Otsuki et al., 2012
Mesothelioma	Human	↑ Apoptosis	Nogi et al., 2012
RCC4-VHL renal cancer	Human	↑ Apoptosis	Nagaya et al., 2013
T/C-28a2 chondrocytes	Human	↓ IL-6, IL-8, PGE2, VEGF	Vincenzi et al., 2013
hFOB 1.19 osteoblasts	Human	↓ IL-6, IL-8, PGE2	Vincenzi et al., 2013

Cronstein, 2004) (Fig. 3). In transfected CHO cells, the ability of both recombinant hA$_3$ARs to inhibit cAMP accumulation and endogenous A$_3$ARs in RBL-2H3 to stimulate PLC is abolished by pretreatment with pertussis toxin, suggesting a functional coupling of this G$_i$ protein receptor (Ali et al., 1990; Zhou et al., 1992; Varani et al., 2000). Furthermore, A$_3$ARs signaling could increase phosphatidylinositol-specific PLC activity (Ali et al., 1990; Ramkumar et al., 1993; Abbracchio et al., 1995; Zheng et al., 2007) and cause the release of Ca^{2+} from intracellular stores in different cellular models (Gessi et al., 2001, 2002; Merighi et al., 2001; Englert et al., 2002; Fossetta et al., 2003; Shneyvays

et al., 2004, 2005; Kim et al., 2012). In a broad study of site-directed mutagenesis of the A$_3$AR, the mutation of the highly conserved tryptophan (W6.48) in the transmembrane domain 6 of GPCRs was first characterized (Gao et al., 2002). Recently, it was reported that this residue plays an important role in determining the structural basis of agonist efficacy and ligand bias in activating A$_3$AR intracellular signaling (Stoddart et al., 2014).

In addition to GPCR recruitment, it has been reported that A$_3$AR stimulation activates other important pathways, such as the monomeric G protein RhoA and phospholipase D, thus inducing cardioprotection

Borea et al.

Fig. 3. Schematic representation of second messengers and intracellular signaling pathways, downstream targets, mediated by A_3ARs stimulation. Upon activation of the A_3AR by adenosine 1) the $G\alpha$ subunit is dissociated from the receptor and $G\beta\gamma$ and decreases AC catalytic activity and cAMP production; 2) PLC is activated leading to Ca^{2+} increase or PI3K, Akt phosphorylation; 3) G protein RhoA and PLD are stimulated; 4) MAPK family, ERKs, JNK, p38, is modulated; and 5) K_{ATP} channels are opened. The final targets downstream these pathways are a series of transcription factors, such as NF-κB, CREB, HIF-1α, c-myc. Thus, A_3AR can elicit multiple signaling pathways within a cell.

(Lee et al., 2001; Mozzicato et al., 2004). In cardiac cells, A_3AR triggers sarcolemmal K_{ATP} channels, mediating A_3AR-dependent protection from ischemia/reperfusion (IR) injury (Tracey et al., 1998; Wan et al., 2008). However, the opening of a mitochondrial K_{ATP} channel has also been proposed as the end effector of the late preconditioning obtained through A_3AR stimulation in mice (Zhao and Kukreja, 2002).

Considerable evidence supports the involvement of protein kinase C (PKC) in both early and delayed preconditioning (Liu et al., 1994). In particular ischemic preconditioning-mediated cardioprotection has been achieved through A_{2B}/A_3AR stimulation of PKCϵ-triggered aldehyde dehydrogenase type-2 activation in cardiac mast cells (Koda et al., 2010). As for delayed preconditioning, PKCδ has been shown to play an essential role in the cellular signaling cascade that produces the protective effect of A_3AR stimulation in the mouse heart (Zhao and Kukreja, 2003). Cl$^-$ channel activation by ischemic preconditioning and a nonselective A_1/A_3AR agonist has also been revealed as a mechanism inducing protection against ischemia/reperfusion injury by enhancing cell volume regulation (Diaz et al., 2010).

Moreover PLC, PKC, or chelation of intracellular Ca^{2+} has been implicated in the reduction of excitotoxicity and in the increase of neuroprotection through the activation of metabotropic glutamate receptor 1 and A_3AR (Dennis et al., 2011). PKC is also involved in the stimulatory effect induced by Cl-IB-MECA on tumor

necrosis factor α (TNF-α) release in lipopolysaccharide (LPS)-stimulated macrophages (Forte et al., 2011).

There is considerable evidence for A_3AR-mediated effects on MAPKs in a multitude of different cellular models (Merighi et al., 2010). The first example of A_3AR-mediated activation of extracellular signal-regulated kinases (ERK1/2) and the modulation of mitogenesis was described in human fetal astrocytes (Neary et al., 1998). Subsequent and more detailed studies have been performed in CHO cells stably expressing A_3AR (Schulte and Fredholm, 2000). A_3AR signaling to ERK1/2 in CHO cells proved to be dependent on $\beta\gamma$ release from pertussis toxin–sensitive G proteins, phosphoinositide 3-kinase (PI3K), Ras, and MAP kinase kinase (MEK) (Schulte and Fredholm, 2002). Importantly, there are several examples of ERK1/2 phosphorylation mediated by endogenously expressed A_3AR, e.g., in both primary mouse microglia cells and the N13 microglia cell line, in colon carcinoma, glioblastoma, and in foam cells (Hammarberg et al., 2003; Merighi et al., 2006, 2007a,b; Gessi et al., 2010a, b). In contrast, in melanoma cells, A_3AR stimulation is unable to activate ERK phosphorylation, whereas A_3AR antagonists are able to improve MEK activity (Fishman et al., 2002b; Merighi et al., 2002a). Indeed, it was demonstrated that A_3AR inhibits A375 melanoma cell proliferation by impairment of ERK activation, a discrepancy that may be due to the presence of different signaling pathways in different cell lines, possibly due to crosstalk between the PI3K/AKT and ERK1/2 pathways

(Merighi et al., 2005b). In addition, in prostate cancer cells, A₃AR inhibits ERK1/2 activity through the reduction of AC and protein kinase A (Jajoo et al., 2009). In glioma, Cl-IB-MECA mediates suppression of ERK1/2, thus inducing caspase-dependent cell death (Kim et al., 2012). Inhibition of ERK1/2 is also associated with the A₃AR inhibition of LPS-stimulated TNF-α release in mouse RAW 264.7 cells (Martin et al., 2006). Importantly, MAPK activation has been implicated in IR injury where ERK1/2 exerts a cytoprotective effect, whereas p38 and c-Jun amino-terminal kinase promote cell injury and death. It has been reported that pretreatment with A₃AR agonists upregulates phosphorylated ERK1/2 levels, inducing a marked improvement in lung injury and attenuation of apoptosis after reperfusion (Matot et al., 2006). Interestingly, A₃AR activation in rat cardiomyocytes has proved to increase ERK1/2 phosphorylation by involving $G_{i/o}$ proteins, PKC, and Tyr kinase–dependent/independent pathways (Germack and Dickenson, 2004).

In addition to ERK1/2, there is experimental evidence that A₃ARs also activate p38 MAPKs in several cellular models, e.g., hCHO-A₃, hypoxic melanoma, glioblastoma, and colon carcinoma cells (Hammarberg et al., 2004; Merighi et al., 2005a, 2006, 2007b). This pathway has also been observed in A₃AR-stimulated activity of antidepressant-sensitive serotonin transporters (Zhu et al., 2011). A₃AR activation protects cardiomyocytes from hypoxia via phosphorylation of p38 MAPK, located downstream of the mitochondrial K_{ATP} channel opening (Leshem-Lev et al., 2010). Accordingly, increased phosphorylation of p38 has been found after Cl-IB-MECA treatment, which proves beneficial, protecting the rat heart subjected to ischemia (Hochhauser et al., 2007). In contrast, activation of A₂ₐ and A₃ARs inhibits p38 MAPK and nuclear factor-κB (NF-κB) pathways in human synoviocytes (Varani et al., 2010c). As for c-Jun amino-terminal kinase, activation by A₃AR has been retrieved in microglia, leading to cell migration (Ohsawa et al., 2012), and in glioblastoma cells, mediating an increase in matrix metalloproteinase-9 (MMP-9) (Gessi et al., 2010b).

Another relevant pathway associated with A₃ARs is the PI3K/Akt (Merighi et al., 2003). A₃AR activation triggers phosphorylation of Akt, protecting rat basophilic leukemia 2H3 mast cells from apoptosis by signaling, which involves the βγ subunits of G_i and PI3K-β (Gao et al., 2001). Moreover, it was demonstrated that A₃AR increases Akt phosphorylation in rat cardiomyocytes (Germack et al., 2004). Recently, transient catecholamine administration was found to trigger preconditioning via generation of adenosine and oxygen free radicals (ROS), thus activating the A₃AR, PI3K/Akt and ERK in rat hearts and leading to cardioprotection (Salie et al., 2012). In glioblastoma cells, activation of PI3K-Akt-pBad by A₃AR stimulation was demonstrated to trigger inhibition of paclitaxel-induced apoptosis

(Merighi et al., 2007a). This pathway was also observed in cardiac myocytes subjected to ischemia/hypoxia and reperfusion/reoxygenation (Hussain et al., 2014). In human melanoma A375 and glioblastoma cells, A₃AR stimulation has produced PI3K-dependent phosphorylation of Akt with antiproliferative effect and MMP-9 increase, respectively (Merighi et al., 2005b; Gessi et al., 2010b).

There is accumulating evidence that the anti-inflammatory A₃AR-mediated activity uses the PI3K/Akt and NF-κB signaling pathways. In LPS-treated BV2 microglial cells and in monocytes, A₃AR activation suppresses TNF-α and interleukin (IL)-12 production, respectively, by inhibiting PI3K/Akt and NF-κB activation (Hasko et al., 1998; la Sala et al., 2005; Lee et al., 2006a, 2011). Inhibition of Akt is triggered by A₃AR for the reduction of LPS-mediated hypoxia-inducible-factor 1α (HIF-1α) accumulation in murine astrocytes (Gessi et al., 2013). Downregulation of the PI3K/Akt-NF-κB signaling pathway has also been observed in the inhibitory effect of IB-MECA in adjuvant-induced arthritis and in mesothelioma (Fishman et al., 2006; Madi et al., 2007; Varani et al., 2011a). Recently, it was reported that A₃AR suppresses angiogenesis by inhibiting PI3K/Akt/mammalian target of rapamycin signaling in endothelial cells (Kim et al., 2013). On the other hand, activation of the PI3K/Akt signaling pathway is triggered by A₃AR in B16 melanoma cells and in human skin explants, thus enhancing pigmentation (Madi et al., 2013).

Increasing evidence highlights a crucial involvement of protein kinase A and Akt in the inactivation of glycogen synthase kinase 3β, a key element in the Wnt signaling pathway, generally active during embryogenesis and tumorigenesis to increase cell cycle progression and cell proliferation. This effect has been induced by IB-MECA in melanoma, in hepatocellular carcinoma, in synoviocytes from rheumatoid arthritis (RA) patients, and in adjuvant-induced arthritis rats (Fishman et al., 2002a; Bar-Yehuda et al., 2008; Ochaion et al., 2008).

The number of pathways seen to be triggered by A₃AR makes an in-depth understanding of the complexity of such signaling in different cellular elements and pathologies of paramount importance (Fig. 3).

VII. Biologic Functions and Therapeutic Applications of the A₃ Adenosine Receptor

A. Central Nervous System

There is interest in understanding A₃AR involvement in normal and pathologic conditions of the CNS despite its low expression in the brain (Rivkees et al., 2000; Burnstock et al., 2011). The role of A₃ARs in several diseases is often controversial, depending on acute and chronic agonist administration (Jacobson, 1998; Von Lubitz, 1999). It has been hypothesized that A₃ARs play a protective role in the first phase of

ischemia by decreasing synaptic transmission (Pugliese et al., 2003; Rivera-Oliver and Diaz-Rios, 2014). However, with prolonged A_3AR stimulation the effects transform from protective to injurious, increasing excitotoxicity (Pugliese et al., 2007).

A proconvulsant effect of A_3ARs has been observed in the immature brain, suggesting that it may facilitate seizure-induced neuronal damage (Boison, 2008). Accordingly, it has also been reported that A_3ARs decrease the stability of currents generated by gamma aminobutyric acid in different epileptic tissues, thus suggesting that adenosine antagonists may offer therapeutic opportunities in various forms of human epilepsy (Roseti et al., 2009).

A_3AR agonists have been reported to depress locomotor activity, thus suggesting a possible inhibition of excitatory neurotransmission in cortical neurons (Boison, 2007). Similarly, an increased motor activity has been revealed in A_3AR knockout (KO) mice (Björklund et al., 2008a). It was recently demonstrated that A_3AR receptors are present in the nerve terminal and muscle cells at the neuromuscular junctions. The presence of these receptors in the neuromuscular synapse allows the receptors to be involved in the modulation of transmitter release (Garcia et al., 2014).

A_3AR is able to reduce excitotoxicity and promote neuroprotection in hippocampal CA3 pyramidal neurons, after ischemic damage, through coactivation of mGluR1; the mechanism involved is endocytosis and subsequent degradation of AMPAR protein levels (Dennis et al., 2011; Sebastiao et al., 2012). Neuroprotection has also been observed through inhibition of P2X7 receptor-induced death of rat retinal ganglion cells (Hu et al., 2010).

An upregulation of A_3ARs has been reported in the hippocampus of a transgenic mouse model of Alzheimer's disease where altered oxidative phosphorylation was detected before amyloid deposition, whereas no change has been observed in the brains of Parkinson's patients (von Arnim et al., 2006; Varani et al., 2010b). Interestingly investigations have shown that A_3AR stimulation rapidly enhances the activity of antidepressant-sensitive serotonin transporters and that the stimulation of SERT activity is lost in A_3AR KO mice (Zhu et al., 2011). A_3AR-stimulated SERT activity is primarily mediated by p38 MAPK-linked pathways, thus supporting the idea that the use of agents that selectively block A_3ARs may diminish SERT surface expression and activation. This evidence suggests the use of A_3AR antagonists for the treatment of mood disorders characterized by hyposerotonergic states (Zhu et al., 2007, 2011).

Glial A_3AR activation by high adenosine levels subsequent to brain injury may be implicated in neuro-inflammatory tissue responses (Hammarberg et al., 2003, 2004). A role for A_3AR as dynamically regulated suppressors of A_{2A}-mediated inhibition of proinflammatory cytokine responses was reported in microglial cells where A_3AR signaling may also be involved in the ADP-induced process extension and migration (van der Putten et al., 2009; Ohsawa et al., 2012). In contrast, an anti-inflammatory effect, leading to a reduction in LPS-stimulated TNF-α production and cell migration, was observed in the same cells (Lee et al., 2006a; Choi et al., 2011).

A_3AR stimulation of neuroprotective substances was also shown in mouse astrocytes (Wittendorp et al., 2004). As regards neuroprotection, A_3ARs inhibit LPS-induced HIF-1α accumulation in murine astrocytes, thus resulting in downregulation of the genes involved in inflammation and hypoxic injury, i.e., inducible nitric oxide synthase and $A_{2B}ARs$ receptors, in both normoxic and hypoxic conditions, thus adding a novel mechanism responsible for protective effects against brain injury (Gessi et al., 2013).

To date, several A_3AR neuroprotective and anti-inflammatory effects have been demonstrated although further studies are needed before clinical utility can be achieved.

B. Cardiovascular System

Several studies in neonatal rat cardiomyocytes suggest that A_3AR stimulation produces direct cardioprotective effects (Germack and Dickenson, 2005; McIntosh and Lasley, 2012). Although there is low A_3AR expression in myocardial tissue, a number of works demonstrated that acute treatment with agonists induces protective "anti-ischemic" effects (Auchampach et al., 1997; Tracey et al., 1997; Thourani et al., 1999a,b; Ge et al., 2006, 2010; Xu et al., 2006; Chanyshev et al., 2012). These findings have also been confirmed in A_3AR-overexpressing mice, where infarct size was smaller than in wild-type mice after in vivo regional IR (Shneyvays et al., 2004). Similarly, anti-ischemic effects have been found with positive allosteric modulators as well as with dendrimeric A_3AR agonists (Wan et al., 2011; Du et al., 2012; Chanyshev et al., 2012).

As for the timing of cardioprotection, there is significant evidence that A_3AR activation exerts a cardioprotective effect both before ischemia and during reperfusion (Gessi et al., 2008b; McIntosh and Lasley, 2012). Interestingly, some studies have indicated that protection occurs postischemia through inhibition of either neutrophil-induced reperfusion injury or myocyte apoptotic cell death (Jordan et al., 1999; Maddock et al., 2002); others, instead, have found that pre-ischemic A_3AR activation is effective and necessary for cardioprotection (Thourani et al., 1999a,b). It has been demonstrated that A_3AR agonism is able to trigger an anti-infarct response with either pre-or postischemic treatment (Auchampach et al., 2003). Moreover, A_3AR activation is able to mimic or induce myocardial preconditioning, meaning that transient stimulation of the A_3AR before induction of ischemia leads both to early and to delayed protection (Peart and Headrick,

2007). Preconditioning through AR modulation may have clinical relevance (for example, in cardiac surgery) although pretreatment is rarely permitted in acute myocardial infarction. For this reason, achieving protection from IR injury through administration of the drug after ischemia or during reperfusion would be more useful (Nishat et al., 2012).

A novel prosurvival pathway by which A$_3$ARs ameliorate myocardial ischemia/reperfusion injury is through its effect on caspase-3 activity, MEK1/2-ERK1/2, and PI3K/AKT (Hussain et al., 2014). There is also evidence that A$_3$ARs enhance cellular antioxidant capacity, thus contributing to vasoprotection and reduced cardiac myocyte death and strongly supporting an A$_3$AR-dependent cardioprotective response. These effects have reduced infarct size, inhibited apoptosis, and improved postischemic contractile function (Zhai et al., 2011). According to powerful cardioprotective effects against myocardial injury, A$_3$AR activation has also been found to improve myocardial survival against cardiotoxic side-effects induced by chemotherapy (Sandhu et al., 2014).

A$_3$AR has, moreover, been seen to play a role in the modulation of blood vessel function (Burnstock and Ralevic, 2014). Activation of A$_3$AR leads to endothelium-dependent aortic contraction through cyclooxygenase-1, which may play a role in cardiovascular inflammation, including hypertension and atherosclerosis (Ansari et al., 2007). A$_3$AR has also been shown to 1) inhibit or negatively modulate coronary flow in isolated mouse heart (Talukder et al., 2002), 2) cause vasoconstriction in hamster arterioles (Shepherd et al., 1996), and 3) reverse vascular hyporeactivity after hemorrhagic shock in rats (Zhou et al., 2010). A$_3$AR-mediated vasoconstriction may involve indirect signaling through nonvascular cell types, such as mast cells that may reside within the vascular wall, by releasing such factors as histamine and thromboxane (Tilley et al., 2000; Zhao and Kukreja, 2002). Indeed, A$_3$AR-mediated vasoconstriction has been proved to depend on the inhibition of cAMP accumulation in smooth muscle and in cultured aorta (Talukder et al., 2002). Another pathway linking A$_3$AR to contraction of the mouse aorta is through ROS generation, via activation of NADPH oxidase 2 (El-Awady et al., 2011). It has recently been reported that, via A$_{2B}$ and A$_{2A}$/A$_3$ARs, adenosine induces hyaluronan matrix modulation in the smooth muscle cells of the human coronary artery, thereby increasing smooth muscle cells proliferation, migration, and monocyte adhesion. For this reason, adenosine has been proposed as a regulator of plaque stability and inflammatory cell trafficking in atherosclerosis (Reiss and Cronstein, 2012; Grandoch et al., 2013). However, although a genetic deficiency in the A$_3$AR subtype has been demonstrated as significantly reducing the proliferative potential of aortas in organ culture, it does not attenuate the development of atherosclerotic lesions in response to a high-fat diet or vascular

injury in vivo (Jones et al., 2004). On the other hand, it has been shown that, in hypoxic foam cells, adenosine stimulates HIF-1α accumulation, vascular endothelial growth factor secretion, and foam cell formation, suggesting the potential use of A$_3$AR antagonists in blocking major steps in atherosclerotic plaque development (Gessi et al., 2010a).

In conclusion, in the cardiovascular system, A$_3$AR modulation appears to have an important protective function. However, this area needs greater exploration through clinical studies to confirm the evidence for preclinical models.

C. Pulmonary System

The role of adenosine in regulating the respiratory system is well known and elevated levels of the nucleoside have been found in bronchoalveolar lavage, blood, and exhaled breath condensate of patients with asthma and chronic obstructive pulmonary disease (COPD).

It is known that A$_3$ARs may be involved in both pro- or anti-inflammatory responses depending on the cell type involved (Salvatore et al., 2000). In particular, the strongest evidence for a functional role of A$_3$AR in mast cell activation comes from the use of genetic A$_3$AR and mast cell KO mice where degranulation appears to depend on A$_3$AR activation, thus suggesting that adenosine exposure can result in A$_3$AR-dependent airway inflammation (Tilley et al., 2003). Likewise, adenosine fails to induce histamine release from lung mast cells obtained from A$_3$AR KO mice and mediated airway hyperresponsiveness by both A$_3$AR-dependent and -independent mechanisms in rodents (Zhong et al., 2003). Accordingly, in A$_3$AR KO mice the reconstitution of wild-type mast cells restores the airway hyperresponsiveness (Hua et al., 2008). In contrast, in a bleomycin model of pulmonary inflammation and fibrosis, A$_3$ARs have provided anti-inflammatory functions, regulating production of the mediators involved in fibrosis (Morschl et al., 2008; Burnstock et al., 2012). Although A$_3$AR protein has not been found in human lung mast cells, it is highly present in human eosinophils with anti-inflammatory functions (Reeves et al., 2000; Hasko et al., 2008). As A$_3$ARs inhibit degranulation of eosinophils, it has been speculated that specific A$_3$AR agonists might be useful in eosinophil-dependent allergic disorders, such as asthma and rhinitis (Spicuzza et al., 2006). However, adenosine deaminase KO mice treated with selective A$_3$AR antagonists have shown a marked attenuation of pulmonary inflammation, decreased eosinophil infiltration, and reduced airway mucus production (Young et al., 2004).

Interestingly, COPD patients have shown decreased A$_{2B}$AR density and increases in A$_{2A}$ and A$_3$ARs in peripheral lung compared with the levels found in smokers with normal lung function (Varani et al., 2006). An increase in A$_3$ARs found in bronchoalveolar

lavage macrophages from COPD patients appears to be closely associated with the presence of high levels of proinflammatory cytokines. In a human leukemic monocyte lymphoma cell line (U937), IL-1β, and TNF-α are both able to bring about significant increases in A$_{2A}$ and A$_3$AR density (Varani et al., 2010). In contrast, A$_3$AR agonists have been suggested as a potential effective therapy for IR-induced lung injury (Matot et al., 2006). Indeed, inosine has been seen to have anti-inflammatory effects in allergic lung inflammation by recruiting A$_3$ARs (da Rocha Lapa et al., 2013). Accordingly, A$_3$AR activation was recently found to attenuate lung IR injury through a neutrophil-dependent mechanism, suggesting the use of A$_3$AR agonists as a novel therapeutic strategy to prevent lung IR injury and primary graft dysfunction after transplantation (Gazoni et al., 2010; Mulloy et al., 2013).

The role of A$_3$AR in the human lung has still to be clarified, although data in recent literature would appear to lean toward a protective effect.

D. Immune System and Inflammation

A$_3$ARs are present in immune cells and are involved in the physiopathologic regulation of inflammatory and immune processes mediated by adenosine (Antonioli et al., 2010; Hasko and Cronstein, 2013).

Neutrophil behavior is strongly affected by the A$_3$AR mediating inhibition of the oxidative burst and chemotaxis with anti-inflammatory activity (Bouma et al., 1997; Gessi et al., 2002; van der Hoeven et al., 2008). Accordingly, these effects have also been observed in a model of severe IR injury after lung transplantation (Mulloy et al., 2013). On the other hand, it was also reported that, together with P2Y2, A$_3$AR guides neutrophil chemotaxis after ATP release (Chen et al., 2006) and also plays a role in neutrophil migration by positively affecting innate immune response (Butler et al., 2012). In particular, this adenosine subtype aggregates in immunomodulatory microdomains on human neutrophil membranes and promotes the formation of bacteria-tethering cytonemes, which are important for phagocytosis, thus suggesting a key role in innate immune response (Corriden et al., 2013).

Adenosine has been proposed as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumors (Hoskin et al., 1994a,b, 2002). The nucleoside interferes with activation-induced expression of the costimulatory molecules CD2 and CD28, possibly through A$_3$AR recruitment (Butler et al., 2003). However, the adenosine-mediated inhibitory effect on the ability of lymphokine-activated killer cells to kill tumor cells has essentially been attributed to the cAMP-elevating A$_{2A}$AR (Raskovalova et al., 2005). In contrast to the immunosuppressive role of adenosine in the environment of solid tumors, A$_3$AR stimulates murine bone marrow cell proliferation in vitro through the production of the granulocyte colony-stimulating factor

by human peripheral blood mononuclear cells (PBMC). Accordingly, when administered before chemotherapy, adenosine increases leukocyte and neutrophil numbers (Fishman et al., 2000). In addition, A$_3$AR activation has been found to enhance natural killer (NK) cell activity and most likely the NK cell-mediated destruction of tumor cells (Harish et al., 2003). Therefore, it is well established that, within the solid tumor microenvironment, adenosine is an important inhibitor of tumor cell destruction by NK and lymphokine-activated killer cell signaling, primarily through the A$_{2A}$ and A$_3$ARs on the surface of T cells (Hoskin et al., 2008). Indeed, ex vivo activation of CD8$^+$ T cells with the A$_3$AR agonist improves adoptive immunotherapy for melanoma (Montinaro et al., 2012). We emphasize that the identification of signal transduction pathways, through which adenosine exerts its inhibitory effects on cell-mediated antitumor immune responses, may allow for the development of focused pharmacologic strategies to reduce, or ablate, the impact of adenosine-mediated immune suppression in cancer patients (Kumar, 2013).

Adenosine is an endogenous regulator of monocyte-macrophage functions, first producing high amounts of inflammatory mediators during the early stages of inflammation and later participating in the resolution of this process. As for the role A$_3$ARs play in the inhibition of macrophage production of TNF-α, discrepant results have been obtained. For example, some studies attributed reduction of TNF-α to A$_3$AR in both human and mouse species (Sajjadi et al., 1996; McWhinney et al., 1996; Lee et al., 2006a), whereas others, using ARs KO mice, found this effect to be mediated essentially by A$_{2A}$AR and, to a lesser extent by A$_{2B}$AR, without A$_3$AR involvement (Kreckler et al., 2006). Still others found that Cl-IB-MECA is able to enhance TNF-α production in LPS-treated macrophages in an NF-κB–dependent manner (Forte et al., 2011). Further macrophage functions regulated by A$_3$AR include the reduction of the chemokine macrophage inflammatory protein (MIP) 1α and the inhibition of interferon regulatory factor 1, inducible nitric oxide synthase, and CD36 gene expression in RAW264.7 murine and THP-1 human cells (Hasko et al., 1996; Barnholt et al., 2009). In addition, IB-MECA inhibits the respiratory burst of human monocytes by blocking NADPH oxidase activity (Broussas et al., 1999; Thiele et al., 2004). In addition to inflammatory mediator modulation, A$_3$AR may be involved in human ventricular remodeling by stimulating MMP-9 production, relevant for revascularization, supporting the use of A$_3$AR agonists during the remodeling phase (Velot et al., 2008). Although most studies indicate a role for A$_3$AR agonists as inhibitors of inflammation, a recent novel application of A$_3$AR antagonists was discovered for a novel series of truncated nucleosides, i.e., that of inhibiting TGF-β1–induced collagen I upregulation, making them appear as good therapeutic

candidates for treating renal fibrosis (Nayak et al., 2014).

Dendritic cells are antigen-presenting cells that are specialized to activate naive T lymphocytes and initiate primary immune responses (Gessi et al., 2009). The role of A$_3$ARs in regulating mature dendritic cell function is less well established (Koscso et al., 2011). It has been reported that A$_1$ and A$_3$ARs are predominantly expressed in immature human dendritic cells and that their stimulation induces Ca^{2+} mobilization from intracellular stores, actin polymerization, and chemotaxis (Panther et al., 2001). Mature dendritic cells, however, downregulate A$_3$ARs and mainly present A$_{2A}$ARs, and both these subtypes inhibit TNF-α release in the mouse dendritic cell line XS-106 (Dickenson et al., 2003).

A$_3$AR activation affects numerous mast cell functions in rodents and humans including degranulation, apoptosis, and regulation of vasopermeability (Gao et al., 2001; Feoktistov et al., 2003). Studies performed on cellular and animal models have shown that A$_3$AR increases degranulation in rodents (Ramkumar et al., 1993; Reeves et al., 1997; Salvatore et al., 2000; Smith et al., 2002; Zhong et al., 2003). Although in the past there was no evidence that the A$_3$AR played a similar role in human mast cells, recently this effect was reported in human LAD2 mast cells (Feoktistov and Biaggioni, 1995; Ryzhov et al., 2004; Leung et al., 2014). A$_3$ARs are also emerging in the treatment of bowel inflammation, because IB-MECA markedly reduces colon levels of such proinflammatory cytokines as IL-1, IL-6, and IL-12 and decreases local production of MIP-1α or MIP-2, thus providing a powerful leukocyte downregulation in bowel inflammation (Mabley et al., 2003). Different studies have evaluated the effects of A$_3$AR agonists on gene dysregulation and tissue injury in rat models of colitis. A$_3$AR agonists prevent the induction of various cytokine/chemokine/inflammatory genes and promote marked suppression of ROS production, which leads to significant amelioration of intestinal injury. In the stomach, jejunum, colon ileum, cecum, and liver, A$_3$AR upregulation has been observed during colitis to provide anti-inflammatory processes in the intestine and liver (Mabley et al., 2003; Lee et al., 2006b). Inhibition of IL-2, TNF-α, and IFN-γ production and upregulation of IL-10 have been observed in cultured splenocytes derived from CF101-treated animals, thus pointing toward a marked anti-inflammatory effect (Bar-Yehuda et al., 2011).

More recently, A$_3$ARs were found to be overexpressed in different autoimmune disorders such as Crohn's disease and psoriasis. The upregulation observed in these pathologies could be attributed to adenosine, which, under conditions of stress, accumulates in the extracellular environment. Most transcription factors, such as NF-κB and CREB, have been revealed as promoting inflammation and being inversely associated with A$_3$AR upregulation (Ochaion et al., 2009). Accordingly, CF101 was tested in a phase II, multicenter, randomized, double-blind, dose-ranging, placebo-controlled trial in patients with moderate to severe chronic plaque-type psoriasis. In this study the drug was found to be safe and well tolerated, and the improvement was progressive and linear throughout the period examined (David et al., 2012). As a consequence, CF101 has entered a phase II/III randomized, double-blind, placebo-controlled, dose-finding study of the efficacy and safety of daily CF101 administered orally in patients with moderate to severe plaque psoriasis (ClinicalTrials.gov).

Overall, the data in the literature suggest that A$_3$AR activation can induce important anti-inflammatory effects in several cellular models. The results achieved thus far with A$_3$AR agonists in clinical studies on such major inflammatory conditions as arthritis and psoriasis are quite promising, and we are confident that they will be translated into treatments for other flogosis-related pathologies.

E. Rheumatoid Arthritis and Ostheoarthritis

Rheumatoid Arthritis is a chronic autoimmune inflammatory disorder of unknown etiology that affects approximately 1% of the population worldwide (Varani et al., 2010a). It is widely accepted that, to prevent unfavorable outcome, RA must be treated early with effective therapy (Flogel et al., 2012). Although, in recent years, great progress has been made in this direction, particularly using biologic drugs, to date no univocal, effective, and safe pharmacologic treatment is available.

Knowledge of the effects of adenosine has revealed that ARs could be a useful target for RA therapy. Adenosine production has emerged as an important cell mechanism to regulate inflammation due to an increase in receptor density and/or functionality. A$_3$ARs are upregulated in RA, psoriasis, and Crohn's disease (Ochaion et al., 2009). Interestingly they are also overexpressed in untreated RA patients and in methotrexate-treated RA patients, and administration of anti–TNF-α drugs normalizes their number and functionality (Varani et al., 2009). Furthermore, A$_3$AR density inversely correlates with Disease Activity Score in 28 or 44 joints, suggesting a direct role of the endogenous activation of these receptors in the control of RA inflammation (Varani et al., 2011b). The overexpression of A$_3$ARs in RA has been directly linked to the increase in NF-κB, a key player in the pathogenesis of arthritic diseases (Bar-Yehuda et al., 2007; Ochaion et al., 2009).

In RA patients, adenosine suppresses the elevated levels of proinflammatory cytokines such as TNF-α and IL-1β, and clinical evidence has shown that A$_3$AR agonists modulate an improvement in signs and symptoms of the disease (Forrest et al., 2005; Silverman et al., 2008). Furthermore, A$_3$AR agonists prevent

cartilage damage, osteoclast/osteophyte formation, bone destruction, and markedly reduce pannus and lymphocyte formation in rat models (Rath-Wolfson et al., 2006; Bar-Yehuda et al., 2009). The anti-inflammatory effect of A_3ARs has also been observed in fibroblast-like synoviocytes derived from the synovial fluid of RA patients and is closely associated with a decrease in NF-κB and TNF-α release (Ochaion et al., 2008). Oral treatment with CF101 has led to amelioration and a marked decrease in clinical manifestations of the disease. In a phase I study in healthy subjects, CF101 proved safe and well tolerated, offering linear pharmacokinetic activity (van Troostenburg et al., 2004). This was confirmed in a now successfully concluded phase II study in RA patients in which CF101 mediated improvement in signs and symptoms, thus suggesting an opportunity for its development as an antirheumatic agent (Silverman et al., 2008; ClinicalTrials.gov).

The most common form of arthritis is osteoarthritis (OA), which is the most important cause of disability in older adults. The current recommended treatment of OA involves weight loss, physical therapy, and the use of pain relievers. However, these drugs do not reverse the degenerative process in OA and show some adverse effects on cartilage metabolism (Zhang et al., 2008). It is well known that p38 MAPKs are involved in controlling such cellular responses as adenosine-mediated proinflammatory cytokine release (Fotheringham et al., 2004). Accordingly, a pathway involving the reduction in p38 MAPKs, NF-κB, TNF-α, and IL-8 by A_3AR activation was observed in human synoviocytes (Varani et al., 2010c). It was also reported that the NF-κB signaling pathway is deregulated by the presence of IB-MECA and is involved in OA pathogenesis. In addition, CF101 induces inflammatory cell apoptosis and acts as a cartilage protective agent, suggesting that it may be a suitable candidate for the treatment of OA (Bar-Yehuda et al., 2009). The safety and efficacy of CF101 has also been evaluated in a phase II clinical study with patients suffering from OA of the knee (Fishman et al., 2012).

Interestingly, a link has been found between ARs and their modulation by such physical agents as pulsed electromagnetic fields (PEMFs). In vitro studies on joint cells have suggested that exposure to PEMFs mediates a significant protection against the catabolic effect of proinflammatory cytokines and an anabolic action increasing matrix synthesis and cell proliferation (Fini et al., 2013). Moreover, PEMFs are able to mediate the upregulation of A_3ARs in bovine chondrocytes and synoviocytes (Varani et al., 2008; De Mattei et al., 2009). These data have been further confirmed in human synoviocytes where the copresence of A_3ARs and PEMFs reduces the release of PGE2, IL-6, and IL-8, whereas it increases IL-10 release (Ongaro et al., 2012). Recently, in human T/C-28a2 chondrocytes and

human FOB 1.19 osteoblasts, PEMFs and A_3AR stimulation have been seen to reduce PGE2, IL-6, and IL-8 production, suggesting their potential in the treatment of inflammatory bone and joint disorders (Vincenzi et al., 2013). Therefore, PEMFs could be an innovative physiologic alternative to the use of agonists as they can mediate the tissue-specific agonist effects without any desensitization and downregulation. All the above indicates that PEMFs could be a very interesting example of "soft pharmacology."

Overall, in joint diseases, the behavior of A_3AR strongly suggests that it could play a therapeutic role in this area and underlines the need for further pharmacologic investigation into how the inflammatory conditions closely associated with these diseases are modulated.

F. Muscle System

It is a well reported fact that IR can cause significant injury in skeletal muscle, because this is the most vulnerable tissue in the extremities (Blaisdell, 2002). Therefore protecting skeletal muscle from IR insult is an important aim of therapy to ameliorate muscle and organ injury (Tsuchida et al., 2003).

A_3ARs have been found to protect the skeletal muscle against IR damage. Interestingly, the A_3AR agonist is a prime candidate for pharmacologic intervention in the first few hours postinjury based on several working hypotheses concerning its mechanism of protection. The pathway involves PLC $\beta2/\beta3$, which in turn activates PKC via diacylglycerol (Zheng et al., 2007). PKC has been shown to activate K_{ATP} channels and cause protection. That adenosine and ischemic preconditioning of the skeletal muscle have an energy-sparing effect is consistent with a consequence of sarcolemmal K_{ATP} channel activation. The latter can cause an abbreviation of the muscle action potential duration, reduce Ca^{2+} influx and overload, and thus ameliorate ischemic injury (Liang et al., 2010). Furthermore, the role of the A_3AR agonist in mitigating Ca^{2+} influx and overload, through its effect on PKC signaling, can potentially decrease MMP activation and subsequent upregulation of downstream proteolytic cascades (Liang et al., 2010).

Another mechanism of A_3AR protection is its anti-inflammatory effect, exerted not at the skeletal muscle level but at the immune cell level. In this signaling pathway, A_3AR activation on circulating immune cells suppresses their function and decreases immune cell-mediated damage to the skeletal muscle. This concept is supported by the finding that activated mast cells and neutrophils are important contributors to, if not mediators of, skeletal muscle IR damage (Fishman et al., 2012).

G. Eye Diseases

A_3ARs have been widely implicated in many ocular diseases including dry eyes, glaucoma, and uveitis. When compared with normal eyes, A_3AR mRNA and protein

levels are found to be consistently increased in the nonpigmented ciliary epithelium in pseudoexfoliation syndrome with glaucoma (Schlotzer-Schrehardt et al., 2005).

In the past, A$_3$AR KO mice showed lower intracellular pressure, thus suggesting that A$_3$AR antagonists could play a role in the treatment of glaucoma (Yang et al., 2005). In addition, the use of A$_3$AR antagonists appears to be a specific, alternate approach for treating ocular hypertension in patients affected by the pseudoexfoliation syndrome in open angle glaucoma, which is typically associated with anterior chamber hypoxia and elevated intraocular pressure (IOP) (Yang et al., 2005). Accordingly, a series of nucleoside-derived antagonists have been found to lower IOP across species (Wang et al., 2010). Recently, it was reported that adenosine may trigger oligodendrocyte death via activation of A$_3$AR, suggesting that this mechanism contributes to optic nerve and white matter ischemic damage (González-Fernández et al., 2014).

On the other hand, it was shown that, in retinal ganglion cells, A$_3$AR prevents activation of the P2X$_7$/NMDA receptors responsible for the rise in Ca^{2+} and apoptosis, thus suggesting the neuroprotective potential of A$_3$AR agonists in glaucoma treatment. These findings were confirmed in in vivo experiments (Zhang et al., 2006b, 2010; Hu et al., 2010). CF101 entered a clinical phase of drug development. Studies from a phase II clinical trial revealed that it was well tolerated and induced a statistically significant improvement in patients with moderate to severe dry eye syndrome. Interestingly, in the same clinical trial, CF101 decreased IOP, thus demonstrating its efficacy as an IOP-lowering agent. These data, and the anti-inflammatory characteristics of CF-101, support pursuing study of this drug as a potential treatment of the signs and symptoms of dry eye syndrome and glaucoma (Avni et al., 2010; Fishman et al., 2013). Indeed now CF101 has entered a phase II, randomized, double-masked, placebo-controlled, parallel-group study of the safety and efficacy of daily CF101 administered orally in subjects with elevated intraocular pressure (ClinicalTrials.gov).

CF101 has also been effective in an experimental model of autoimmune uveitis, supporting further exploration of this molecule for the treatment of uveitis (Bar-Yehuda et al., 2011). Oral treatment with CF101, initiated upon disease onset, improves clinical uveitis fundoscopy score and ameliorates the pathologic manifestations of the disease. Now CF101 has entered a phase II, randomized, double-masked, placebo-controlled study of the safety and efficacy of daily CF101 administered orally in subjects with active, sight-threatening, noninfectious intermediate or posterior uveitis (ClinicalTrials.gov).

H. Cancer

A very interesting area of possible application for A$_3$AR ligands is in cancer therapy. The possibility that A$_3$AR may play a role in the development of cancer was suggested several years ago (Fishman et al., 1998, 2000; Merighi et al., 2003; Gessi et al., 2011b).

Adenosine is present at high levels in cancer tissues and in the interstitial fluid of several tumors, in sufficient concentration to interact with ARs (Blay et al., 1997; Antonioli et al., 2013). In particular, A$_3$ARs are present in different types of tumor cells, such as HL60 and K562 human leukemia (Gessi et al., 2002), Jurkat (Gessi et al., 2001), and U937 human lymphoma (Gessi et al., 2010a), Nb2 rat lymphoma (Fishman et al., 2000), A375 human melanoma (Merighi et al., 2001), PGT-beta mouse tumor pineal gland (Suh et al., 2001), human glioblastoma (Merighi et al., 2006; Gessi et al., 2010b), human prostatic (Jajoo et al., 2009), and mesothelioma cells (Varani et al., 2011a). A$_3$AR subtype overexpression has also been demonstrated in colon cancer tissues, compared with normal mucosa, obtained from patients undergoing surgery (Gessi et al., 2004a; Madi et al., 2004). Upregulation in tissues is reflected in peripheral blood cells, thus making this adenosine subtype a possible marker for cancer (Gessi et al., 2004a). Another study showed upregulated A$_3$AR mRNA expression in hepatocellular carcinoma (HCC) tissues compared with adjacent normal tissues (BarYehuda et al., 2008). Remarkably, upregulation of A$_3$AR was noted in PBMCs derived from HCC patients compared with healthy subjects. Interestingly, these results suggest that, in PBMCs, A$_3$AR reflects receptor status in remote tumor tissue (Gessi et al., 2004a). Similarly, in malignant mesothelioma pleura, mRNA, and protein expression of A$_3$ARs have been found statistically increased with respect to healthy mesothelial pleura (Varani et al., 2011a).

Clinical investigations have clearly shown that the prevalence of hypoxic tissue areas is a specific property of solid tumors (Melillo et al., 2004). Furthermore, hypoxia appears to induce increased intracellular adenosine levels and stabilize the most important factors involved in hypoxia, such as HIF-1α. A$_3$ARs stimulation induces HIF-1α accumulation in different cancer cell lines (Merighi et al., 2005a, 2006). This has been seen to lead to an increase in angiopoietin-2 and/or vascular endothelial growth factor, depending on the cell model investigated (Merighi et al., 2007b).

As for the role the A$_3$AR subtype plays in cancer cells, several other functions have been described. Both pro- and antiapoptotic as well as pro- and antiproliferative effects have been reported depending on the level of receptor activation (Jacobson, 1998; Merighi et al., 2005b; Gessi et al., 2007; Kim et al., 2010; Taliani et al., 2010; Varani et al., 2011a; Sakowicz-Burkiewicz et al., 2013). At first, telomerase activity inhibition and cytostatic effects were observed in tumor cells (Fishman et al., 2000, 2001). Then the intracellular pathway involved in A$_3$AR-mediated tumor growth inhibition was identified (Fishman et al., 2004, 2012). In contrast,

some studies showed that A_3AR agonist inhibition of cell proliferation was only obtained by micromolar concentrations (Lu et al., 2003; Merighi et al., 2005b; Nakamura et al., 2006). Furthermore, in U87MG cells, A_3AR stimulation induced an increase in MMP-9, through the AP-1 activation responsible for increased glioblastoma cell invasion, as observed in macrophages (Velot et al., 2008; Gessi et al., 2010b). However, other studies reported that A_3ARs reduces the ability of prostate cancer cells to migrate in vitro and metastasize in vivo (Jajoo et al., 2009). Accordingly, in the same cells, IB-MECA inhibits cell proliferation and induces G1 cell cycle arrest, apoptosis, and migration (Morello et al., 2009; Aghaei et al., 2011). Stimulation of A_3ARs exerts a cytotoxic and proapoptotic effect on malignant mesothelioma cells (Varani et al., 2011a). Interestingly, the antitumor effect of A_3ARs is potentiated by PEMFs in cultured neural cancer cells such as PC12 and U87MG glioblastoma cells, thus decreasing NF-κB activation and cell proliferation. Moreover, PEMF and A_3AR stimulation are able to significantly increase p53 levels, cytotoxicity, and apoptosis in tumor cells (Vincenzi et al., 2012).

A_3AR agonists have also been investigated in in vivo studies. In all the experimental models, given their stability and bioavailability profile, the drugs were administered orally. The studies included syngeneic, xenograft, orthotopic, and metastatic experimental animal models utilizing IB-MECA and Cl-IB-MECA in melanoma, colon, prostate, and hepatocellular carcinomas. A_3AR agonists prevented the growth of primary B16-F10 murine melanoma tumors in syngeneic models. Moreover, in an artificial metastatic model, IB-MECA inhibited the development of B16-F10 murine melanoma lung metastases. Response specificity was demonstrated by A_3AR antagonist administration which reversed the effect of the agonist. Furthermore, in combination with the chemotherapeutic agent cyclophosphamide, IB-MECA, or Cl-IB-MECA induced an additive antitumor effect on the development of B16-F10 melanoma lung metastatic foci (Fishman et al., 2009). In addition, the combination of Cl-IB-MECA and paclitaxel caused significant cytotoxicity on two melanoma cell lines through multiple mechanisms of cell death (Soares et al., 2014). Furthermore, in xenograft models, IB-MECA counteracted the development of human colon and prostate carcinoma in nude mice. In these studies, the combined treatment with IB-MECA and 5-fluorouracil or taxol, respectively, resulted in an enhanced antitumor effect. IB-MECA prevented the growth of primary and liver metastases of CT-26 colon carcinoma cells inoculated in the spleen. Finally, Cl-IB-MECA treatment dose dependently inhibited hepatocellular tumor growth and reduced liver inflammation (Gao and Jacobson, 2007; Bar-Yehuda et al., 2008; Fishman et al., 2009; Cohen et al., 2011). Accordingly, Cl-IB-MECA significantly reduced tumor growth and

cancer pain in rat bone-residing breast cancer (Varani et al., 2013).

The safety and clinical effects of CF102 were assessed in patients with advanced unresectable HCC, in a phase I/II trial. This study included 18 hepatocellular carcinoma patients treated with three different doses of CF102 to determine the pharmacokinetic behavior and safety profile of long-term administration (Stemmer et al., 2013). Owing to its safety and favorable pharmacokinetic characteristics, phase II trial for advanced liver cancer is ongoing (ClinicalTrials.gov).

Overall, these data suggest that A_3ARs might be a biologic tumor marker and that A_3AR modulation could be used to treat cancer.

I. Pain

Chronic neuropathic pain is a major unresolved health care issue with global human and socioeconomic impact (5–10% occurrence in Europe and the United States). Its general incidence is augmented by pain from chemotherapy-induced peripheral neuropathy. Therefore, the identification of novel therapeutic targets that can effectively resolve this condition would be necessary.

The contribution of A_3AR in pain states has been evaluated in different studies. A nociceptive and proinflammatory response resulting in edema formation was first demonstrated after activation of A_3AR; this effect was mediated by both serotonin and histamine release, most likely from mast cells and subsequent actions on the sensory nerve terminal (Sawynok et al., 1997). Then, there was less heat hyperalgesia after carrageenan in A_3ARKO mice probably due to reduced inflammation (Wu et al., 2002). Furthermore, investigation of the behavioral effects of A_3ARKO mice showed a decreased sensitivity to some painful stimuli (Fedorova et al., 2003). However an opposite activity in pain modulation was observed in further studies. Intrathecal delivery of IB-MECA attenuated the inflammatory component of the formalin test (Yoon et al., 2005). In addition, recently, the treatment of chronic neuropathic pain was proposed as a novel potential application of A_3AR agonists (Paoletta et al., 2013). A_3AR agonists blocked the development of mechanically and chemotherapy-induced neuropathic pain in a dose-dependent fashion and significantly augmented the analgesic effects of currently used analgesics (Chen et al., 2012). Accordingly, in an animal model of surgery-induced metastasis Cl-IB-MECA significantly reduced bone cancer pain, providing the pharmacologic rationale for using selective A_3AR agonists as a new approach in chronic neuropathic pain (Varani et al., 2013). Interestingly, very recently, the first mechanistic insight into beneficial effects of A_3AR agonists against neuropathic pain has been explored (Janes et al., 2014a,b). In particular it has been found that these effects were due to the inhibition of an astrocyte-associated neuroinflammatory

response in a model of oxaliplatin-induced peripheral neuropathy (Janes et al., 2014b). Furthermore A$_3$AR agonists were found to prevent the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways (Janes et al., 2014a).

Importantly, the activation of A$_3$AR in humans by potent, selective, and orally bioavailable A$_3$AR agonists is not associated with cardiac or hemodynamic side effects at variance with A$_1$ and A$_{2A}$ ARs and could represent a viable therapeutic strategy for chronic pain of distinct etiologies. There is evidence for both central and peripheral sites of action of A$_3$AR agonists in protection against chronic neuropathic pain, and there is a need for new pharmacologic tools to explore this phenomenon. The biochemical basis underlying the protective and beneficial effects of A$_3$AR agonists in chronic neuropathic pain is unknown and deserves further in depth investigation. It has been hypothesized that mitoprotective effects and/or attenuation of neuroinflammatory processes in spinal cord mediate the underlying protective A$_3$AR role.

From a translational perspective, this could hopefully lead to a rapid investigation of A$_3$AR agonists, already in clinical trials, for neuropathic pain treatment.

VIII. Recent Drug Development Efforts

Allosteric modulation of GPCRs now represents one of the most exciting areas in modern drug discovery. One GPCR system that is of particular interest with respect to allosteric modulation is adenosine and its A$_3$AR subtype.

Today our knowledge of the GPCR structure has been substantially improved by providing greater understanding of the conformational changes that occur when an agonist binds to the receptor at the same site as the endogenous ligand, the so-called orthosteric site (Chung et al., 2011; Rasmussen et al., 2011; Hill et al., 2014). However, in recent years it has become evident that drugs can also bind to a topographically distinct site (allosteric) on the GPCR protein and induce conformational changes that modify the affinity, or efficacy, of a ligand occupying the classic orthosteric binding site (Kenakin, 2009, 2012; Keov et al., 2011). Key molecular scaffolds that support allosteric modulation at the A$_3$AR have been identified, 3-(2-pyridinyl)isoquinolines (e.g., VUF5455) and [^{3}H]imidazo-[4,5-c]quinolin-4-amines (e.g., LUF5999, LUF6000, and LUF6001), with differing effects on the affinity and efficacy of a selective A$_3$AR agonist (Goblyos et al., 2009; Can-fite Biopharma, 2010; Gao et al., 2011) (Fig. 4). LUF6000 was shown to enhance agonist efficacy in a functional assay and decrease agonist dissociation rate without affecting agonist potency.

In an attempt to overcome the issues associated with the orthosteric antagonism shown by 3-(2-pyridinyl)

isoquinolines, a series of ring opened imidazoquinolin-amines were synthesized to afford a range of 2,4-disubstituted quinolines as a new class of A$_3$AR allosteric enhancers (Heitman et al., 2009). Notably, the best compound (LUF6096) was not only able to allosterically enhance the binding of Cl-IB-MECA to a similar level as LUF6000, but also displayed negligible orthosteric affinity for any of the AR subtypes. The ubiquitous distribution of ARs and the potential for serious side effects via the target receptor in a different organ or cell type can limit their utility. Allosteric enhancers may represent a strategy to overcome these limitations. However, although in vitro studies have provided convincing evidence for allosteric mechanisms of action for a number of ligands, therapeutic application of these mechanisms relies on their successful translation into whole animal physiology. The efficacy of LUF6096 in an in vivo model of infarction has been shown to be a good starting point (Du et al., 2012). Indeed, LUF6096 had no effect on baseline hemodynamic parameters; however, pretreatment with LUF6096 before coronary occlusion and during reperfusion produced a marked reduction in infarct size (Du et al., 2012). An equivalent reduction was also demonstrated if LUF6096 was administered immediately before reperfusion (Du et al., 2012). It would therefore appear that allosteric enhancers of A$_3$AR may prove to be highly useful therapeutic strategies, selectively augmenting the actions of adenosine released locally under conditions of disease and stress. However, more in-depth investigation is required into the potential of these molecules to increase selective actions of adenosine in specific organs and cell types in whole animal.

Another original effort to improve A$_3$AR activation has been the attachment of methanocarba adenosine derivatives to PAMAM dendrimers (Jacobson and Melman, 2010) (Fig. 4). Dendrimers are tree-like polymers widely used in in vivo drug delivery that can serve as biocompatible polymeric nanocarriers of bioactive molecules of interest (Menjoge et al., 2010). These multivalent GPCR ligand-dendrimer conjugates display pharmacologic properties that are qualitatively different from those of monomeric drugs and might be useful as novel tools to study GPCR homo- and hetero-dimers and higher aggregates. Assuming proper functionalization of a ligand for covalent conjugation, the resulting GPCR ligand-dendrimer conjugates have displayed dramatically increased potency or selectivity in comparison with the monomeric, small molecular ligands (Kim et al., 2008a; Jacobson, 2010). The use of nanocarriers for stably conjugated drugs that act at the cell surface may provide pharmacokinetic and pharmacodynamic advantages, such as the prevention of premature degradation (Kim et al., 2008a; Jacobson, 2010). These derivatives have been claimed for the treatment of inflammation, cardiac ischemia, stroke, asthma, diabetes,

Fig. 4. Representative A$_3$AR allosteric modulators and dendrimers.

IX. Concluding Remarks

and cardiac arrhythmias (Jacobson and Melman, 2009). Interestingly, it has been demonstrated that the PAMAM dendrimer conjugate specifically activates A$_3$ARs to improve postischemic/reperfusion function in isolated mouse hearts (Wan et al., 2011). Similar results were confirmed in rat primary cardiac cell cultures and in the isolated heart where these strategically derivatized nucleosides display enhanced cardioprotective potency (Chanyshev et al., 2012). In vivo testing will now be needed to explore the effects on pharmacokinetics and tissue targeting. The potential of this approach for use in animal models of disease is still to be proven, and such important points as cellular uptake, pharmacologic effects of ligands binding to adjacent GPCR proteins, changes in selectivity according to conjugate composition, and side effects all need to be addressed (Jacobson, 2010).

Investigation of A$_3$ARs and their ligands is rapidly growing and having an increasing impact on the drug discovery process. There is now extensive evidence that A$_3$ARs are involved in the physiologic regulation of several homeostatic processes and in the etiology of many diseases (Fig. 5). The present review documents the state of knowledge of the adenosine A$_3$AR. It covers a wide range of information, including data from studies of theoretical, molecular and cellular pharmacology, signal transduction, new drug discoveries, and clinical applications. Detailed understanding of the physicochemical aspects and molecular biology of the A$_3$AR provides a solid basis for its future development as a target for adenosine-based pharmacotherapies. Recognition and characterization of intracellular

Fig. 5. Schematic diagram illustrating the functional role of A₃ARs. Activation of the A₃AR pathway by adenosine can affect a number of organs, including pulmonary, immune, cardiovascular, muscle and central nervous system, and pathologies like eye, joint diseases, and cancer, thus regulating various biologic outcomes.

pathways modulated by A₃AR activation support the belief that modulating these signaling routes is likely to lead to considerable advances in the management of many diseases. The identification of new, potent, and selective A₃AR ligands opens new frontiers for the elucidation of the therapeutic potential arising from stimulating or blocking the A₃AR. The A₃AR appears to play a prominent role under ischemic conditions and remains a promising target for treating neurodegenerative diseases associated with acute ischemia. In terms of clinical utility, it will be critical to explore in greater detail the efficacy of the A₃AR-mediated protective response in diseased hearts and skeletal muscle. There is emerging evidence that the A₃AR may be a good target in neuropathic pain. A₃ARs are present in all immune cells and are involved in the regulation of inflammatory and immune processes, suggesting new therapeutic strategies may emerge for inflammatory conditions such as sepsis, asthma, and autoimmune disorders including rheumatoid arthritis, Crohn's disease, and psoriasis. The oral bioavailability of certain A₃AR agonists together with encouraging data from clinical studies support the development of these

agents as antirheumatic drugs. The effectiveness of the A₃AR agonist Cl-IB-MECA in several animal tumor models has led to the introduction of this molecule into a program of clinical studies. The excellent safety profile has brought about the initiation of phase II clinical studies in patients with hepatocellular carcinoma, which are currently ongoing. Based on the important scientific and clinical advances overviewed in this review, it would seem that purine scientists are definitely getting closer to their goal of transforming adenosine ligands into drugs with the ability to save lives and improve human health.

References

Abbracchio MP, Brambilla R, Ceruti S, Kim HO, von Lubitz DK, Jacobson KA, and Cattabeni F (1995) G protein-dependent activation of phospholipase C by adenosine A₃ receptors in rat brain. *Mol Pharmacol* **48**:1038–1045.
Abbracchio MP, Camurri A, Ceruti S, Cattabeni F, Falzano L, Giammarioli AM, Jacobson KA, Trincavelli L, Martini C, and Malorni W, et al. (2001) The A₃ adenosine receptor induces cytoskeleton rearrangement in human astrocytoma cells via a specific action on Rho proteins. *Ann N Y Acad Sci* **939**:63–73.
Abbracchio MP, Rainaldi G, Giammarioli AM, Ceruti S, Brambilla R, Cattabeni F, Barbieri D, Franceschi C, Jacobson KA, and Malorni W (1997) The A₃ adenosine

receptor mediates cell spreading, reorganization of actin cytoskeleton, and distribution of Bcl-XL: studies in human astroglioma cells. *Biochem Biophys Res Commun* **241**:297–304.

Aghaei M, Panjehpour M, Karami-Tehrani F, and Salami S (2011) Molecular mechanisms of A₃ adenosine receptor-induced G1 cell cycle arrest and apoptosis in androgen-dependent and independent prostate cancer cell lines: involvement of intrinsic pathway. *J Cancer Res Clin Oncol* **137**:1511–1523.

Ali H, Cunha-Melo JR, Saul WF, and Beaven MA (1990) Activation of phospholipase C via adenosine receptors provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells. Evidence for a novel adenosine receptor. *J Biol Chem* **265**:745–753.

Ansari HR, Nadeem A, Tilley SL, and Mustafa SJ (2007) Involvement of COX-1 in A₃ adenosine receptor-mediated contraction through endothelium in mice aorta. *Am J Physiol Heart Circ Physiol* **293**:H3448–H3455.

Antonioli L, Blandizzi C, Pacher P, and Haskó G (2013) Immunity, inflammation and cancer: a leading role for adenosine. *Nat Rev Cancer* **13**:842–857.

Antonioli L, Fornai M, Colucci R, Ghisu N, Tuccori M, Awwad O, Bin A, Zoppellaro C, Castagliuolo I, and Gaion RM, et al. (2010) Control of enteric neuromuscular functions by purinergic A₃ receptors in normal rat distal colon and experimental bowel inflammation. *Br J Pharmacol* **161**:856–871.

Atkinson MR, Townsend-Nicholson A, Nicholl JK, Sutherland GR, and Schofield PR (1997) Cloning, characterisation and chromosomal assignment of the human adenosine A₃ receptor (ADORA3) gene. *Neurosci Res* **29**:73–79.

Auchampach JA, Ge Z-D, Wan TC, Moore J, and Gross GJ (2003) A₃ adenosine receptor agonist IB-MECA reduces myocardial ischemia-reperfusion injury in dogs. *Am J Physiol Heart Circ Physiol* **285**:H607–H613.

Auchampach JA, Rizvi A, Qiu Y, Tang XL, Maldonado C, Teschner S, and Bolli R (1997) Selective activation of A₃ adenosine receptors with N6-(3-iodobenzyl)adenosine-5′-N-methyluronamide protects against myocardial stunning and infarction without hemodynamic changes in conscious rabbits. *Circ Res* **80**:800–809.

Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, and Tomkins O, et al. (2010) Treatment of dry eye syndrome with orally administered CF101: data from a phase 2 clinical trial. *Ophthalmology* **117**:1287–1293.

Baraldi PG, Cacciari B, Moro S, Spalluto G, Pastorin G, Da Ros T, Klotz KN, Varani K, Gessi S, and Borea PA (2002) Synthesis, biological activity, and molecular modeling investigation of new pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as human A(3) adenosine receptor antagonists. *J Med Chem* **45**:770–780.

Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Klotz KN, Leung E, Varani K, Gessi S, Merighi S, and Borea PA (1999) Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists. *J Med Chem* **42**:4473–4478.

Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, Moro S, Klotz K-N, Leung E, Varani K, Gessi S, and Merighi S, et al. (2000) Pyrazolo[4,3-e]1,2,4-triazolo[1,5-c]pyrimidine derivatives as highly potent and selective human A(3) adenosine receptor antagonists: influence of the chain at the N(8) pyrazole nitrogen. *J Med Chem* **43**:4768–4780.

Baraldi PG, Fruttarolo F, Tabrizi MA, Preti D, Romagnoli R, El-Kashef H, Moorman A, Varani K, Gessi S, and Merighi S, et al. (2003) Design, synthesis, and biological evaluation of C9- and C2-substituted pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as new A₂ₐ and A₃ adenosine receptors antagonists. *J Med Chem* **46**:1229–1241.

Baraldi PG, Preti D, Borea PA, and Varani K (2012) Medicinal chemistry of A₃ adenosine receptor modulators: pharmacological activities and therapeutic implications. *J Med Chem* **55**:5676–5703.

Barbieri D, Abbracchio MP, Salvioli S, Monti D, Cossarizza A, Ceruti S, Brambilla R, Cattabeni F, Jacobson KA, and Franceschi C (1998) Apoptosis by 2-chloro-2′-deoxy-adenosine and 2-chloro-adenosine in human peripheral blood mononuclear cells. *Neurochem Int* **32**:493–504.

Barnholt KE, Kota RS, Aung HH, and Rutledge JC (2009) Adenosine blocks IFN-γ-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. *J Immunol* **183**:6767–6777.

Bar-Yehuda S, Luger D, Ochaion A, Cohen S, Patokaa R, Zozulya G, Silver PB, de Morales JM, Caspi RR, and Fishman P (2011) Inhibition of experimental autoimmune uveitis by the A₃ adenosine receptor agonist CF101. *Int J Mol Med* **28**:727–731.

Bar-Yehuda S, Madi L, Barak D, Mittelman M, Ardon E, Ochaion A, Cohn S, and Fishman P (2002) Agonists to the A3 adenosine receptor induce G-CSF production via NF-kappaB activation: a new class of myeloprotective agents. *Exp Hematol* **30**:1390–1398.

Bar-Yehuda S, Rath-Wolfson L, Del Valle L, Ochaion A, Cohen S, Patoka R, Zozulya G, Barer F, Atar E, and Piña-Oviedo S, et al. (2009) Induction of an antiinflammatory effect and prevention of cartilage damage in rat knee osteoarthritis by CF101 treatment. *Arthritis Rheum* **60**:3061–3071.

Bar-Yehuda S, Silverman MH, Kerns WD, Ochaion A, Cohen S, and Fishman P (2007) The anti-inflammatory effect of A₃ adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. *Expert Opin Investig Drugs* **16**:1601–1613.

Bar-Yehuda S, Stemmer SM, Madi L, Castel D, Ochaion A, Cohen S, Barer F, Zabutti A, Perez-Liz G, and Del Valle L, et al. (2008) The A₃ adenosine receptor agonist CF102 induces apoptosis of hepatocellular carcinoma via de-regulation of the Wnt and NF-kappaB signal transduction pathways. *Int J Oncol* **33**:287–295.

Björklund O, Halldner-Henriksson L, Yang J, Eriksson TM, Jacobson MA, Daré E, and Fredholm BB (2008a) Decreased behavioral activation following caffeine, amphetamine and darkness in A3 adenosine receptor knock-out mice. *Physiol Behav* **95**:668–676.

Björklund O, Shang M, Tonazzini I, Daré E, and Fredholm BB (2008b) Adenosine A₁ and A₃ receptors protect astrocytes from hypoxic damage. *Eur J Pharmacol* **596**:6–13.

Blay J, White TD, and Hoskin DW (1997) The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine. *Cancer Res* **57**:2602–2605.

Blaisdell FW (2002) The pathophysiology of skeletal muscle ischemia and the reperfusion syndrome: a review. *Cardiovasc Surg* **10**:620–630.

Boison D (2007) Adenosine as a modulator of brain activity. *Drug News Perspect* **20**:607–611.

Boison D (2008) The adenosine kinase hypothesis of epileptogenesis. *Prog Neurobiol* **84**:249–262.

Borea PA, Dalpiaz A, Varani K, Gilli P, and Gilli G (2000) Can thermodynamic measurements of receptor binding yield information on drug affinity and efficacy? *Biochem Pharmacol* **60**:1549–1556.

Bouma MG, Jeunhomme TM, Boyle DL, Dentener MA, Voitenok NN, van den Wildenberg FAJM, and Buurman WA (1997) Adenosine inhibits neutrophil degranulation in activated human whole blood: involvement of adenosine A2 and A3 receptors. *J Immunol* **158**:5400–5408.

Brand A, Vissiennon Z, Eschke D, and Nieber K (2001) Adenosine A(1) and A(3) receptors mediate inhibition of synaptic transmission in rat cortical neurons. *Neuropharmacology* **40**:85–95.

Brandon CI, Vandenplas M, Dookwah H, and Murray TF (2006) Cloning and pharmacological characterization of the equine adenosine A₃ receptor. *J Vet Pharmacol Ther* **29**:255–263.

Broussas M, Cornillet-Lefèbvre P, Potron G, and Nguyen P (1999) Inhibition of fMLP-triggered respiratory burst of human monocytes by adenosine: involvement of A₃ adenosine receptor. *J Leukoc Biol* **66**:495–501.

Broussas M, Cornillet-Lefèbvre P, Potron G, and Nguyên P (2002) Adenosine inhibits tissue factor expression by LPS-stimulated human monocytes: involvement of the A₃ adenosine receptor. *Thromb Haemost* **88**:123–130.

Burnett LA, Blais EM, Unadkat JD, Hille B, Tilley SL, and Babcock DF (2010) Testicular expression of Adora3i2 in Adora3 knockout mice reveals a role of mouse A3Ri2 and human A3Ri3 adenosine receptors in sperm. *J Biol Chem* **285**:33662–33670.

Burnstock G, Brouns I, Adriaensen D, and Timmermans JP (2012) Purinergic signaling in the airways. *Pharmacol Rev* **64**:834–868.

Burnstock G, Fredholm BB, and Verkhratsky A (2011) Adenosine and ATP receptors in the brain. *Curr Top Med Chem* **11**:973–1011.

Burnstock G and Ralevic V (2014) Purinergic signaling and blood vessels in health and disease. *Pharmacol Rev* **66**:102–192.

Butler JJ, Mader JS, Watson CL, Zhang H, Blay J, and Hoskin DW (2003) Adenosine inhibits activation-induced T cell expression of CD2 and CD28 co-stimulatory molecules: role of interleukin-2 and cyclic AMP signaling pathways. *J Cell Biochem* **89**:975–91.

Butler M, Sanmugalingam D, Burton VJ, Wilson T, Pearson R, Watson RP, Smith P, and Parkinson SJ (2012) Impairment of adenosine A₃ receptor activity disrupts neutrophil migratory capacity and impacts innate immune function in vivo. *Eur J Immunol* **42**:3358–3368.

Calzetta L, Spina D, Cazzola M, Page CP, Facciolo F, Rendina EA, and Matera MG (2011) Pharmacological characterization of adenosine receptors on isolated human bronchi. *Am J Respir Cell Mol Biol* **45**:1222–1231.

Can-fite Biopharma Ltd. (2010) A₃ adenosine receptor allosteric modulators. US0144156.

Carruthers AM and Fozard JR (1993) Adenosine A₃ receptors: two into one won't go. *Trends Pharmacol Sci* **14**:290–291.

Chanyshev B, Shainberg A, Isak A, Litinsky A, Chepurko Y, Tosh DK, Phan K, Gao ZG, Hochhauser E, and Jacobson KA (2012) Anti-ischemic effects of multivalent dendrimeric A₃ adenosine receptor agonists in cultured cardiomyocytes and in the isolated rat heart. *Pharmacol Res* **65**:338–346.

Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, and Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A₃ receptors. *Science* **314**:1792–1795.

Chen Z, Janes K, Chen C, Doyle T, Bryant L, Tosh DK, Jacobson KA, and Salvemini D (2012) Controlling murine and rat chronic pain through A3 adenosine receptor activation. *FASEB J* **26**:1855–1865.

Choi IY, Lee JC, Ju C, Hwang S, Cho GS, Lee HW, Choi WJ, Jeong LS, and Kim WK (2011) A₃ adenosine receptor agonist reduces brain ischemic injury and inhibits inflammatory cell migration in rats. *Am J Pathol* **179**:2042–2052.

Christofi FL, Zhang H, Yu JG, Guzman J, Xue J, Kim M, Wang Y-Z, and Cooke HJ (2001) Differential gene expression of adenosine A₁, A₂ₐ, and A₃ receptors in the human enteric nervous system. *J Comp Neurol* **439**:46–64.

Chung KY, Rasmussen SGF, Liu T, Li S, DeVree BT, Chae PS, Calinski D, Kobilka BK, Woods VL Jr, and Sunahara RK (2011) Conformational changes in the G protein Gs induced by the β2 adrenergic receptor. *Nature* **477**:611–615.

Cinalli AR, Guarracino JF, Fernandez V, Roquel LI, and Losavio AS (2013) Inosine induces presynaptic inhibition of acetylcholine release by activation of A₃ adenosine receptors at the mouse neuromuscular junction. *Br J Pharmacol* **169**:1810–1823.

Cohen S, Stemmer SM, Zozulya G, Ochaion A, Patoka R, Barer F, Bar-Yehuda S, Rath-Wolfson L, Jacobson KA, and Fishman P (2011) CF102 an A₃ adenosine receptor agonist mediates anti-tumor and anti-inflammatory effects in the liver. *J Cell Physiol* **226**:2438–2447.

Corriden R, Self T, Akong-Moore K, Nizet V, Kellam B, Briddon SJ, and Hill SJ (2013) Adenosine-A₃ receptors in neutrophil microdomains promote the formation of bacteria-tethering cytonemes. *EMBO Rep* **14**:726–732.

Cross HR, Murphy E, Black RG, Auchampach J, and Steenbergen C (2002) Overexpression of A(₃) adenosine receptors decreases heart rate, preserves energetics, and protects ischemic hearts. *Am J Physiol Heart Circ Physiol* **283**:H1562–H1568.

da Rocha Lapa F, de Oliveira AP, Accetturi BG, de Oliveira Martins I, Domingos HV, de Almeida Cabrini D, de Lima WT, and Santos AR (2013) Anti-inflammatory effects of inosine in allergic lung inflammation in mice: evidence for the participation of adenosine A₂ₐ and A₃ receptors. *Purinergic Signal* **9**:325–336.

David M, Akerman L, Ziv M, Kadurina M, Gospodinov D, Pavlotsky F, Yankova R, Kouzeva V, Ramon M, and Silverman MH, et al. (2012) Treatment of plaque-type psoriasis with oral CF101: data from an exploratory randomized phase 2 clinical trial. *J Eur Acad Dermatol Venereol* **26**:361–367.

Decking UK, Schlieper G, Kroll K, and Schrader J (1997) Hypoxia-induced inhibition of adenosine kinase potentiates cardiac adenosine release. *Circ Res* **81**:154–164.

De Mattei M, Varani K, Masieri FF, Pellati A, Ongaro A, Fini M, Cadossi R, Vincenzi F, Borea PA, and Caruso A (2009) Adenosine analogs and electromagnetic fields inhibit prostaglandin E2 release in bovine synovial fibroblasts. *Osteoarthritis Cartilage* **17**:252–262.

DeNinno MP, Masamune H, Chenard LK, DiRico KJ, Eller C, Etienne JB, Tickner JE, Kennedy SP, Knight DR, and Kong J, et al. (2003) 3′-Aminoadenosine-5′-uronamides: discovery of the first highly selective agonist at the human adenosine A₃ receptor. *J Med Chem* **46**:353–355.

Dennis SH, Jaafari N, Cimarosti H, Hanley JG, Henley JM, and Mellor JR (2011) Oxygen/glucose deprivation induces a reduction in synaptic AMPA receptors on hippocampal CA3 neurons mediated by mGluR1 and adenosine A₃ receptors. *J Neurosci* **31**:11941–11952.

Diaz RJ, Hinek A, and Wilson GJ (2010) Direct evidence of chloride ion efflux in ischaemic and pharmacological preconditioning of cultured cardiomyocytes. *Cardiovasc Res* **87**:545–551.

Dickenson JM, Reeder S, Rees B, Alexander S, and Kendall D (2003) Functional expression of adenosine A₂ₐ and A₃ receptors in the mouse dendritic cell line XS-106. *Eur J Pharmacol* **474**:43–51.

Di Tullio MA, Tayebati SK, and Amenta F (2004) Identification of adenosine A₁ and A₃ receptor subtypes in rat pial and intracerebral arteries. *Neurosci Lett* **366**: 48–52.

Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, and Freeman TC (1996) Tissue distribution of adenosine receptor mRNAs in the rat. *Br J Pharmacol* **118**: 1461–1468.

Drabczyńska A, Schumacher B, Müller CE, Karolak-Wojciechowska J, Michalak B, Pekala E, and Kieć-Kononowicz K (2003) Impact of the aryl substituent kind and distance from pyrimido[2,1-f]purindiones on the adenosine receptor selectivity and antagonistic properties. *Eur J Med Chem* **38**:397–402.

Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, and Auchampach JA (2012) Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor. *J Pharmacol Exp Ther* **340**:210–217.

Dunwiddie TV, Diao L, Kim HO, Jiang J-L, and Jacobson KA (1997) Activation of hippocampal adenosine A₃ receptors produces a desensitization of A₁ receptor-mediated responses in rat hippocampus. *J Neurosci* **17**:607–614.

El-Awady MS, Ansari HR, Fil D, Tilley SL, and Mustafa SJ (2011) NADPH oxidase pathway is involved in aortic contraction induced by A₃ adenosine receptor in mice. *J Pharmacol Exp Ther* **338**:711–717.

el-Hashim A, D'Agostino B, Matera MG, and Page C (1996) Characterization of adenosine receptors involved in adenosine-induced bronchoconstriction in allergic rabbits. *Br J Pharmacol* **119**:1262–1268.

Englert M, Quitterer U, and Klotz KN (2002) Effector coupling of stably transfected human A₃ adenosine receptors in CHO cells. *Biochem Pharmacol* **64**:61–65.

Fedorova IM, Jacobson MA, Basile L, and Jacobson KA (2003) Behavioral characterization of mice lacking the A3 adenosine receptor: sensitivity to hypoxic neurodegeneration. *Cell Mol Neurobiol* **23**:431–447.

Feoktistov I and Biaggioni I (1995) Adenosine A₂ᵦ receptors evoke interleukin-8 secretion in human mast cells. An enprofylline-sensitive mechanism with implications for asthma. *J Clin Invest* **96**:1979–1986.

Feoktistov I, Ryzhov S, Goldstein AE, and Biaggioni I (2003) Mast cell-mediated stimulation of angiogenesis: cooperative interaction between A₂ᵦ and A₃ adenosine receptors. *Circ Res* **92**:485–492.

Fernandez P, Jara C, Aguilera V, Caviedes L, Diaz F, Radojkovic C, Veas C, Lamperti L, Escudero C, and Aguayo C (2012) Adenosine A₂ₐ and A₃ receptors are involved in the human endothelial progenitor cells migration. *J Cardiovasc Pharmacol* **59**: 397–404.

Fini M, Pagani S, Giavaresi G, De Mattei M, Ongaro A, Varani K, Vincenzi F, Massari L, and Cadossi R (2013) Functional tissue engineering in articular cartilage repair: is there a role for electromagnetic biophysical stimulation? *Tissue Eng Part B Rev* **19**:353–367.

Fishman P, Bar-Yehuda S, Ardon E, Rath-Wolfson L, Barrer F, Ochaion A, and Madi L (2003) Targeting the A₃ adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A₃AR agonist. *Anticancer Res* **23** (3A): 2077–2083.

Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AS, and Pathak S (2001) The A₃ adenosine receptor as a new target for cancer therapy and chemoprotection. *Exp Cell Res* **269**:230–236.

Fishman P, Bar-Yehuda S, Liang BT, and Jacobson KA (2012) Pharmacological and therapeutic effects of A₃ adenosine receptor agonists. *Drug Discov Today* **17**: 359–366.

Fishman P, Bar-Yehuda S, Madi L, and Cohn I (2002a) A₃ adenosine receptor as a target for cancer therapy. *Anticancer Drugs* **13**:437–443.

Fishman P, Bar-Yehuda S, Madi L, Rath-Wolfson L, Ochaion A, Cohen S, and Baharav E (2006) The PI3K-NF-kappaB signal transduction pathway is involved in mediating the anti-inflammatory effect of IB-MECA in adjuvant-induced arthritis. *Arthritis Res Ther* **8**:R169.

Fishman P, Bar-Yehuda S, Ohana G, Barer F, Ochaion A, Erlanger A, and Madi L (2004) An agonist to the A₃ adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B. *Oncogene* **23**:2465–2471.

Fishman P, Bar-Yehuda S, Ohana G, Pathak S, Wasserman L, Barer F, and Multani AS (2000) Adenosine acts as an inhibitor of lymphoma cell growth: a major role for the A₃ adenosine receptor. *Eur J Cancer* **36**:1452–1458.

Fishman P, Bar-Yehuda S, Synowitz M, Powell JD, Klotz KN, Gessi S, and Borea PA (2009) Adenosine receptors and cancer. *Handbook Exp Pharmacol* **193**:399–441.

Fishman P, Bar-Yehuda S, and Vagman L (1998) Adenosine and other low molecular weight factors released by muscle cells inhibit tumor cell growth. *Cancer Res* **58**: 3181–3187.

Fishman P, Cohen S, and Bar-Yehuda S (2013) Targeting the A₃ adenosine receptor for glaucoma treatment (review). *Mol Med Rep* **7**:1723–1725.

Fishman P, Madi L, Bar-Yehuda S, Barer F, Del Valle L, and Khalili K (2002b) Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells. *Oncogene* **21**:4060–4064.

Flögel U, Burghoff S, van Lent PL, Temme S, Galbarz L, Ding Z, El-Tayeb A, Huels S, Bönner F, and Borg N, et al. (2012) Selective activation of adenosine A2A receptors on immune cells by a CD73-dependent prodrug suppresses joint inflammation in experimental rheumatoid arthritis. *Sci Transl Med* **4**:146ra108.

Forrest CM, Harman G, McMillan RB, Stoy N, Stone TW, and Darlington LG (2005) Modulation of cytokine release by purine receptors in patients with rheumatoid arthritis. *Clin Exp Rheumatol* **23**:89–92.

Forte G, Sorrentino R, Montinaro A, Pinto A, and Morello S (2011) Cl-IB-MECA enhances TNF-α release in peritoneal macrophages stimulated with LPS. *Cytokine* **54**:161–166.

Fossetta J, Jackson J, Deno G, Fan X, Du XK, Bober L, Soudé-Bermejo A, de Bouteiller O, Caux C, and Lunn C, et al. (2003) Pharmacological analysis of calcium responses mediated by the human A₃ adenosine receptor in monocyte-derived dendritic cells and recombinant cells. *Mol Pharmacol* **63**:342–350.

Fotheringham JA, Mayne MB, Grant JA, and Geiger JD (2004) Activation of adenosine receptors inhibits tumor necrosis factor-alpha release by decreasing TNF-alpha mRNA stability and p38 activity. *Eur J Pharmacol* **497**:87–95.

Fozard JR and Carruthers AM (1993) Adenosine A₃ receptors mediate hypotension in the angiotensin II-supported circulation of the pithed rat. *Br J Pharmacol* **109**:3–5.

Fozard JR, Pfannkuche H-J, and Schuurman H-J (1996) Mast cell degranulation following adenosine A₃ receptor activation in rats. *Eur J Pharmacol* **298**:293–297.

Fozard JR (2010) From Hypertension (+) to Asthma: Interactions with the Adenosine A3 Receptor from a Personal Perspective, in *A₃ Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics* (Borea PA, ed) pp 3–26, Springer, New York.

Fredholm BB (2014) Adenosine—a physiological or pathophysiological agent? *J Mol Med (Berl)* **92**:201–206.

Fredholm BB, IJzerman AP, Jacobson KA, Klotz K-N, and Linden J (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. *Pharmacol Rev* **53**:527–552.

Fredholm BB, IJzerman AP, Jacobson KA, Linden J, and Müller CE (2011) International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors—an update. *Pharmacol Rev* **63**:1–34.

Gallo-Rodriguez C, Ji XD, Melman N, Siegman BD, Sanders LH, Orlina J, Fischer B, Pu Q, Olah ME, and van Galen PJ, et al. (1994) Structure-activity relationships of N6-benzyladenosine-5′-uronamides as A₃-selective adenosine agonists. *J Med Chem* **37**:636–646.

Gao ZG, Chen A, Barak D, Kim SK, Müller CE, and Jacobson KA (2002) Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A3 adenosine receptor. *J Biol Chem* **277**:19056–19063.

Gao ZG and Jacobson KA (2007) Emerging adenosine receptor agonists. *Expert Opin Emerg Drugs* **12**:479–492.

Gao Z, Li BS, Day YJ, and Linden J (2001) A₃ adenosine receptor activation triggers phosphorylation of protein kinase B and protects rat basophilic leukemia 2H3 mast cells from apoptosis. *Mol Pharmacol* **59**:76–82.

Gao ZG, Verzijl D, Zweemer A, Ye K, Göblyös A, Ijzerman AP, and Jacobson KA (2011) Functionally biased modulation of A(₃) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. *Biochem Pharmacol* **82**:658–668.

Garcia N, Priego M, Hurtado E, Obis T, Santafe MM, Tomàs M, Lanuza MA, and Tomàs J (2014) Adenosine A2B and A3 receptor location at the mouse neuromuscular junction. *J Anat* **225**:109–17.

Gatta F, Del Giudice MR, Borioni A, Borea PA, Dionisotti S, and Ongini E (1993) Synthesis of imidazo[1,2-c]pyrazolo[4,3-e]pyrimidines, pyrazolo[4,3-e]1,2,4-triazolo [1,5-c]pyrimidines and 1,2,4-triazolo[5,1-i]purines: new potent adenosine A₂ receptor antagonists. *Eur J Med Chem* **28**:569–576.

Gazoni LM, Walters DM, Unger EB, Linden J, Kron IL, and Laubach VE (2010) Activation of A₁, A₂ₐ, or A₃ adenosine receptors attenuates lung ischemia-reperfusion injury. *J Thorac Cardiovasc Surg* **140**:440–446.

Ge ZD, Peart JN, Kreckler LM, Wan TC, Jacobson MA, Gross GJ, and Auchampach JA (2006) Cl-IB-MECA [2-chloro-N⁶-(3-iodobenzyl)adenosine-5′-N-methylcarboxamide] reduces ischemia/reperfusion injury in mice by activating the A₃ adenosine receptor. *J Pharmacol Exp Ther* **319**:1200–1210.

Ge ZD, van der Hoeven D, Maas JE, Wan TC, and Auchampach JA (2010) A(₃) adenosine receptor activation during reperfusion reduces infarct size through actions on bone marrow-derived cells. *J Mol Cell Cardiol* **49**:280–286.

Germack R and Dickenson JM (2005) Adenosine triggers preconditioning through MEK/ERK1/2 signalling pathway during hypoxia/reoxygenation in neonatal rat cardiomyocytes. *J Mol Cell Cardiol* **39**:429–442.

Germack R and Dickenson JM (2004) Characterization of ERK1/2 signalling pathways induced by adenosine receptor subtypes in newborn rat cardiomyocytes. *Br J Pharmacol* **141**:329–339.

Germack R, Griffin M, and Dickenson JM (2004) Activation of protein kinase B by adenosine A₁ and A₃ receptors in newborn rat cardiomyocytes. *J Mol Cell Cardiol* **37**:989–999.

Gessi S, Cattabriga E, Avitabile A, Gafa' R, Lanza G, Cavazzini L, Bianchi N, Gambari R, Feo C, and Liboni A, et al. (2004a) Elevated expression of A₃ adenosine receptors in human colorectal cancer is reflected in peripheral blood cells. *Clin Cancer Res* **10**:5895–5901.

Gessi S, Fogli E, Sacchetto V, Merighi S, Varani K, Preti D, Leung E, Maclennan S, and Borea PA (2010a) Adenosine modulates HIF-1alpha, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. *Arterioscler Thromb Vasc Biol* **30**:90–97.

Gessi S, Fogli E, Sacchetto V, Varani K, Merighi S, Leung E, Lennan SM, and Borea PA (2008a) Thermodynamics of A_{2B} adenosine receptor binding discriminates agonistic from antagonistic behaviour. *Biochem Pharmacol* 75:562–569.

Gessi S, Merighi S, Fazzi D, Stefanelli A, Varani K, and Borea PA (2011a) Adenosine receptor targeting in health and disease. *Expert Opin Investig Drugs* 20:1591–1609.

Gessi S, Merighi S, Sacchetto V, Simioni C, and Borea PA (2011b) Adenosine receptors and cancer. *Biochim Biophys Acta* 1808:1400–1412.

Gessi S, Merighi S, Stefanelli A, Fazzi D, Varani K, and Borea PA (2013) $A_{(1)}$ and $A_{(3)}$ adenosine receptors inhibit LPS-induced hypoxia-inducible factor-1 accumulation in murine astrocytes. *Pharmacol Res* 76:157–170.

Gessi S, Merighi S, Stefanelli A, Mirandola P, Bonfatti A, Fini S, Sensi A, Marci R, Varani K, and Borea PA, et al. (2012) Downregulation of $A_{(1)}$ and $A_{(2B)}$ adenosine receptors in human trisomy 21 mesenchymal cells from first-trimester chorionic villi. *Biochim Biophys Acta* 1822:1660–1670.

Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, Leung E, Mac Lennan S, Feo C, and Baraldi S, et al. (2007) Adenosine receptors in colon carcinoma tissues and colon tumoral cell lines: focus on the $A_{(3)}$ adenosine subtype. *J Cell Physiol* 211:826–836.

Gessi S, Merighi S, Varani K, Leung E, Mac Lennan S, and Borea PA (2008b) The A_3 adenosine receptor: an enigmatic player in cell biology. *Pharmacol Ther* 117:123–140.

Gessi S, Sacchetto V, Fogli E, and Fozard J(2009) A3 adenosine receptor regulation of cells of the immune system and modulation of inflammation, in *A3 Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics* (Borea PA ed) pp 235–256, Springer, New York.

Gessi S, Sacchetto V, Fogli E, Merighi S, Varani K, Baraldi PG, Tabrizi MA, Leung E, Maclennan S, and Borea PA (2010b) Modulation of metalloproteinase-9 in U87MG glioblastoma cells by A_3 adenosine receptors. *Biochem Pharmacol* 79:1483–1495.

Gessi S, Varani K, Merighi S, Cattabriga E, Avitabile A, Gavioli R, Fortini C, Leung E, Mac Lennan S, and Borea PA (2004b) Expression of A_3 adenosine receptors in human lymphocytes: up-regulation in T cell activation. *Mol Pharmacol* 65:711–719.

Gessi S, Varani K, Merighi S, Cattabriga E, Iannotta V, Leung E, Baraldi PG, and Borea PA (2002) $A_{(3)}$ adenosine receptors in human neutrophils and promyelocytic HL60 cells: a pharmacological and biochemical study. *Mol Pharmacol* 61:415–424.

Gessi S, Varani K, Merighi S, Morelli A, Ferrari D, Leung E, Baraldi PG, Spalluto G, and Borea PA (2001) Pharmacological and biochemical characterization of A_3 adenosine receptors in Jurkat T cells. *Br J Pharmacol* 134:116–126.

Goblyos A, Brussee J, Ijzerman AP, Gao ZJ, and Jacobson K (2009), inventors, Government of the USA, assignee. A_3 adenosine receptor allosteric modulators. US patent 20090054476 A1. 26 Feb 2009.

Gomez G, Zhao W, and Schwartz LB (2011) Disparity in FcεRI-induced degranulation of primary human lung and skin mast cells exposed to adenosine. *J Clin Immunol* 31:479–487.

González-Fernández E, Sánchez-Gómez MV, Pérez-Samartín A, Arellano RO, and Matute C (2014) A_3 Adenosine receptors mediate oligodendrocyte death and ischemic damage to optic nerve. *Glia* 62:199–216.

Grandoch M, Hoffmann J, Röck K, Wenzel F, Oberhuber A, Schelzig H, and Fischer JW (2013) Novel effects of adenosine receptors on pericellular hyaluronan matrix: implications for human smooth muscle cell phenotype and interactions with monocytes during atherosclerosis. *Basic Res Cardiol* 108:340.

Hammarberg C, Fredholm BB, and Schulte G (2004) Adenosine A_3 receptor-mediated regulation of p38 and extracellular-regulated kinase ERK1/2 via phosphatidylinositol-3′-kinase. *Biochem Pharmacol* 67:129–134.

Hammarberg C, Schulte G, and Fredholm BB (2003) Evidence for functional adenosine A_3 receptors in microglia cells. *J Neurochem* 86:1051–1054.

Hannon JP, Pfannkuche HJ, and Fozard JR (1995) A role for mast cells in adenosine A_3 receptor-mediated hypotension in the rat. *Br J Pharmacol* 115:945–952.

Harish A, Hohana G, Fishman P, Arnon O, and Bar-Yehuda S (2003) A_3 adenosine receptor agonist potentiates natural killer cell activity. *Int J Oncol* 23:1245–1249.

Harrison GJ, Cerniway RJ, Peart J, Berr SS, Ashton K, Regan S, Paul Matherne G, and Headrick JP (2002) Effects of $A_{(3)}$ adenosine receptor activation and gene knock-out in ischemic-reperfused mouse heart. *Cardiovasc Res* 53:147–155.

Haskó G and Cronstein BN (2004) Adenosine: an endogenous regulator of innate immunity. *Trends Immunol* 25:33–39.

Haskó G and Cronstein B (2013) Regulation of inflammation by adenosine. *Front Immunol* 4:85.

Haskó G, Linden J, Cronstein B, and Pacher P (2008) Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. *Nat Rev Drug Discov* 7:759–770.

Haskó G, Németh ZH, Vizi ES, Salzman AL, and Szabó C (1998) An agonist of adenosine A_3 receptors decreases interleukin-12 and interferon-gamma production and prevents lethality in endotoxemic mice. *Eur J Pharmacol* 358:261–268.

Haskó G, Pacher P, Vizi ES, and Illes P (2005) Adenosine receptor signaling in the brain immune system. *Trends Pharmacol Sci* 26:511–516.

Haskó G, Szabó C, Németh ZH, Kvetan V, Pastores SM, and Vizi ES (1996) Adenosine receptor agonists differentially regulate IL-10, TNF-alpha, and nitric oxide production in RAW 264.7 macrophages and in endotoxemic mice. *J Immunol* 157:4634–4640.

Headrick JP and Peart J (2005) A_3 adenosine receptor-mediated protection of the ischemic heart. *Vascul Pharmacol* 42:271–279.

Heitman LH, Göblyös A, Zweemer AM, Bakker R, Mulder-Krieger T, van Veldhoven JPD, de Vries H, Brussee J, and Ijzerman AP (2009) A series of 2,4-disubstituted quinolines as a new class of allosteric enhancers of the adenosine A3 receptor. *J Med Chem* 52:926–931.

Hill SJ, May LT, Kellam B, and Woolard J (2014) Allosteric interactions at adenosine $A_{(1)}$ and $A_{(3)}$ receptors: new insights into the role of small molecules and receptor dimerization. *Br J Pharmacol* 171:1102–1113.

Hinze AV, Mayer P, Harst A, and von Kügelgen I (2012) Adenosine $A_{(3)}$ receptor-induced proliferation of primary human coronary smooth muscle cells involving the induction of early growth response genes. *J Mol Cell Cardiol* 53:639–645.

Hochhauser E, Leshem D, Kaminski O, Cheporko Y, Vidne BA, and Shainberg A (2007) The protective effect of prior ischemia reperfusion adenosine A_1 or A_3 receptor activation in the normal and hypertrophied heart. *Interact Cardiovasc Thorac Surg* 6:363–368.

Hofer S, Ivarsson L, Stoitzner P, Auffinger M, Rainer C, Romani N, and Heufler C (2003) Adenosine slows migration of dendritic cells but does not affect other aspects of dendritic cell maturation. *J Invest Dermatol* 121:300–307.

Hofer M, Dušek L, Hoferová Z, Stixová L, and Pospíšil M (2011) Expression of mRNA for adenosine $A_{1(1)}$, $A_{(2a)}$, $A_{(2b)}$, and $A_{(3)}$ receptors in HL-60 cells: dependence on cell cycle phases. *Physiol Res* 60:913–920.

Hoskin DW, Butler JJ, Drapeau D, Haeryfar SM, and Blay J (2002) Adenosine acts through an A_3 adenosine receptor to prevent the induction of murine anti-CD3-activated killer T cells. *Int J Cancer* 99:386–395.

Hoskin DW, Mader JS, Furlong SJ, Conrad DM, and Blay J (2008) Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). *Int J Oncol* 32:527–535.

Hoskin DW, Reynolds T, and Blay J (1994a) Adenosine as a possible inhibitor of killer T-cell activation in the microenvironment of solid tumours. *Int J Cancer* 59:854–855.

Hoskin DW, Reynolds T, and Blay J (1994b) 2-Chloroadenosine inhibits the MHC-unrestricted cytolytic activity of anti-CD3-activated killer cells: evidence for the involvement of a non-A1/A2 cell-surface adenosine receptor. *Cell Immunol* 159:85–93.

Hu H, Lu W, Zhang M, Zhang X, Argall AJ, Patel S, Lee GE, Kim YC, Jacobson KA, and Laties AM, et al. (2010) Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. *Exp Eye Res* 91:425–432.

Hua X, Chason KD, Fredholm BB, Deshpande DA, Penn RB, and Tilley SL (2008) Adenosine induces airway hyperresponsiveness through activation of A_3 receptors on mast cells. *J Allergy Clin Immunol* 122:107–113, e1–e7.

Hussain A, Gharanei AM, Nagra AS, and Maddock HL (2014) Caspase inhibition via A_3 adenosine receptors: a new cardioprotective mechanism against myocardial infarction. *Cardiovasc Drugs Ther* 28:19–32.

Jacobson KA (1998) Adenosine A_3 receptors: novel ligands and paradoxical effects. *Trends Pharmacol Sci* 19:184–191.

Jacobson KA (2010) GPCR ligand-dendrimer (GLiDe) conjugates: future smart drugs? *Trends Pharmacol Sci* 31:575–579.

Jacobson KA, Klutz AM, Tosh DK, Ivanov AA, Preti D, and Baraldi PG (2009) Medicinal chemistry of the A3 adenosine receptor: agonists, antagonists, and receptor engineering. *Handb Exp Pharmacol* 193:123−159.

Jacobson KA and Melman A (2010), inventors. Methanocarba adenosine derivatives and dendrimer conjugated thereof. Patent 20120264769. 2 Dec 2010.

Jacobson KA, Nikodijević O, Shi D, Gallo-Rodriguez C, Olah ME, Stiles GL, and Daly JW (1993) A role for central A3-adenosine receptors. Mediation of behavioral depressant effects. *FEBS Lett* 336:57–60.

Jacobson KA, Park KS, Jiang J-L, Kim YC, Olah ME, Stiles GL, and Ji X-D (1997) Pharmacological characterization of novel A_3 adenosine receptor-selective antagonists. *Neuropharmacology* 36:1157–1165.

Jacobson KA, Siddiqi SM, Olah ME, Ji XD, Melman N, Bellamkonda K, Meshulam Y, Stiles GL, and Kim HO (1995) Structure-activity relationships of 9-alkyladenine and ribose-modified adenosine derivatives at rat A_3 adenosine receptors. *J Med Chem* 38:1720–1735.

Jajoo S, Mukherjea D, Watabe K, and Ramkumar V (2009) Adenosine $A_{(3)}$ receptor suppresses prostate cancer metastasis by inhibiting NADPH oxidase activity. *Neoplasia* 11:1132–1145.

Janes K, Esposito E, Doyle T, Cuzzocrea S, Tosh DK, Jacobson KA, and Salvemini D (2014a) A_3 adenosine receptor agonist prevents the development of paclitaxel-induced neuropathic pain by modulating spinal glial-restricted redox-dependent signaling pathways. *Pain*, in press.

Janes K, Wahlman C, Little JW, Doyle T, Tosh DK, Jacobson KA, and Salvemini D (2014b) Spinal neuroimmune activation is independent of T-cell infiltration and attenuated by A_3 adenosine receptor agonists in a model of oxaliplatin-induced peripheral neuropathy. *Brain Behav Immun*, in press.

Jeong LS, Jin DZ, Kim HO, Shin DH, Moon HR, Gunaga P, Chun MW, Kim YC, Melman N, and Gao ZG, et al. (2003) N^6-substituted D-4′-thioadenosine-5′-methyluronamides: potent and selective agonists at the human A_3 adenosine receptor. *J Med Chem* 46:3775–3777.

Ji XD, Melman N, and Jacobson KA (1996) Interactions of flavonoids and other phytochemicals with adenosine receptors. *J Med Chem* 39:781–788.

Ji XD, von Lubitz D, Olah ME, Stiles GL, and Jacobson KA (1994) Species differences in ligand affinity at central A3-adenosine receptors. *Drug Dev Res* 33:51–59.

Jones MR, Zhao Z, Sullivan CP, Schreiber BM, Stone PJ, Toselli PA, Kagan HM, Cohen RA, and Ravid K (2004) $A_{(3)}$ adenosine receptor deficiency does not influence atherogenesis. *J Cell Biochem* 92:1034–1043.

Jordan JE, Thourani VH, Auchampach JA, Robinson JA, Wang NP, and Vinten-Johansen J (1999) $A_{(3)}$ adenosine receptor activation attenuates neutrophil function and neutrophil-mediated reperfusion injury. *Am J Physiol* 277:H1895–H1905.

Kadomatsu M, Nakajima S, Kato H, Gu L, Chi Y, Yao J, and Kitamura M (2012) Cordycepin as a sensitizer to tumour necrosis factor (TNF)-α-induced apoptosis through eukaryotic translation initiation factor 2α (eIF2α)- and mammalian target of rapamycin complex 1 (mTORC1)-mediated inhibition of nuclear factor (NF)-κB. *Clin Exp Immunol* 168:325–332.

Kamiya H, Kanno T, Fujita Y, Gotoh A, Nakano T, and Nishizaki T (2012) Apoptosis-related gene transcription in human A549 lung cancer cells via $A_{(3)}$ adenosine receptor. *Cell Physiol Biochem* 29:687–696.

Kanno T, Nakano T, Fujita Y, Gotoh A, and Nishizaki T (2012) Adenosine induces apoptosis in SBC-3 human lung cancer cells through $A_{(3)}$ adenosine receptor-dependent AMID upregulation. *Cell Physiol Biochem* 30:666–677.

Kenakin TP (2009) '7TM receptor allostery: putting numbers to shapeshifting proteins. *Trends Pharmacol Sci* 30:460–469.

Kenakin TP (2012) Biased signalling and allosteric machines: new vistas and challenges for drug discovery. *Br J Pharmacol* 165:1659–1669.

Keov P, Sexton PM, and Christopoulos A (2011) Allosteric modulation of G protein-coupled receptors: a pharmacological perspective. *Neuropharmacology* 60:24–35.

Kim Y, Hechler B, Klutz AM, Gachet C, and Jacobson KA (2008a) Toward multivalent signaling across G protein-coupled receptors from poly(amidoamine) dendrimers. *Bioconjug Chem* 19:406–411.

Kim YH, Hwang HS, Kim YT, Kim HS, and Park YW (2008b) Modulation of matrix metalloproteinase secretion by adenosine A$_3$ receptor in preeclamptic villous explants. *Reprod Sci* 15:939–949.

Kim YC, Ji XD, and Jacobson KA (1996) Derivatives of the triazoloquinazoline adenosine antagonist (CGS15943) are selective for the human A3 receptor subtype. *J Med Chem* 39:4142–4148.

Kim HO, Ji XD, Siddiqi SM, Olah ME, Stiles GL, and Jacobson KA (1994) 2-Substitution of N6-benzyladenosine-5′-uronamides enhances selectivity for A3 adenosine receptors. *J Med Chem* 37:3614–3621.

Kim H, Kang JW, Lee S, Choi WJ, Jeong LS, Yang Y, Hong JT, and Yoon Y (2010) A$_3$ adenosine receptor antagonist, truncated Thio-Cl-IB-MECA, induces apoptosis in T24 human bladder cancer cells. *Anticancer Res* 30:2823–2830.

Kim TH, Kim YK, and Woo JS (2012) The adenosine A3 receptor agonist Cl-IB-MECA induces cell death through Ca^{2+}/ROS-dependent down regulation of ERK and Akt in A172 human glioma cells. *Neurochem Res* 37:2667–2677.

Kim GD, Oh J, Jeong LS, and Lee SK (2013) Thio-Cl-IB-MECA, a novel A$_3$ adenosine receptor agonist, suppresses angiogenesis by regulating PI3K/AKT/mTOR and ERK signaling in endothelial cells. *Biochem Biophys Res Commun* 437:79–86.

Klotz KN, Falgner N, Kachler S, Lambertucci C, Vittori S, Volpini R, and Cristalli G (2007) [^{3}H]HEMADO—a novel tritiated agonist selective for the human adenosine A$_3$ receptor. *Eur J Pharmacol* 556:14–18.

Koda K, Salazar-Rodriguez M, Corti F, Chan NY, Estephan R, Silver RB, Mochly-Rosen D, and Levi R (2010) Aldehyde dehydrogenase activation prevents reperfusion arrhythmias by inhibiting local renin release from cardiac mast cells. *Circulation* 122:771–781.

Kohno Y, Ji X, Mawhorter SD, Koshiba M, and Jacobson KA (1996a) Activation of A$_3$ adenosine receptors on human eosinophils elevates intracellular calcium. *Blood* 88:3569–3574.

Kohno Y, Sei Y, Koshiba M, Kim HO, and Jacobson KA (1996b) Induction of apoptosis in HL-60 human promyelocytic leukemia cells by adenosine A(3) receptor agonists. *Biochem Biophys Res Commun* 219:904–910.

Koscsó B, Csóka B, Pacher P, and Haskó G (2011) Investigational A$_3$ adenosine receptor targeting agents. *Expert Opin Investig Drugs* 20:757–768.

Kreckler LM, Wan TC, Ge Z-D, and Auchampach JA (2006) Adenosine inhibits tumor necrosis factor-α release from mouse peritoneal macrophages via A$_{2A}$ and A$_{2B}$ but not the A$_3$ adenosine receptor. *J Pharmacol Exp Ther* 317:172–180.

Kumar V (2013) Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? *Purinergic Signal* 9:145–165.

la Sala A, Gadina M, and Kelsall BL (2005) G(i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. *J Immunol* 175:2994–2999.

Lee HS, Chung HJ, Lee HW, Jeong LS, and Lee SK (2011) Suppression of inflammation response by a novel A$_3$ adenosine receptor agonist thio-Cl-IB-MECA through inhibition of Akt and NF-κB signaling. *Immunobiology* 216:997–1003.

Lee JE, Bokoch G, and Liang BT (2001) A novel cardioprotective role of RhoA: new signaling mechanism for adenosine. *FASEB J* 15:1886–1894.

Lee JY, Jhun BS, Oh YT, Lee JH, Choe W, Baik HH, Ha J, Yoon KS, Kim SS, and Kang I (2006a) Activation of adenosine A3 receptor suppresses lipopolysaccharide-induced TNF-alpha production through inhibition of PI 3-kinase/Akt and NF-kappaB activation in murine BV2 microglial cells. *Neurosci Lett* 396:1–6.

Lee HT, Kim M, Joo JD, Gallos G, Chen JF, and Emala CW (2006b) A$_3$ adenosine receptor activation decreases mortality and renal and hepatic injury in murine septic peritonitis. *Am J Physiol Regul Integr Comp Physiol* 291:R959–R969.

Leshem-Lev D, Hochhauser E, Chanyshev B, Isak A, and Shainberg A (2010) Adenosine A$_1$ and A$_3$ receptor agonists reduce hypoxic injury through the involvement of P38 MAPK. *Mol Cell Biochem* 345: 153–160.

Leung CT, Li A, Banerjee J, Gao ZG, Kambayashi T, Jacobson KA, and Civan MM (2014) The role of activated adenosine receptors in degranulation of human LAD2 mast cells. *Purinergic Signal* 10:465–475.

Li AH, Moro S, Melman N, Ji XD, and Jacobson KA (1998) Structure-activity relationships and molecular modeling of 3, 5-diacyl-2,4-dialkylpyridine derivatives as selective A$_3$ adenosine receptor antagonists. *J Med Chem* 41:3186–3201.

Liang BT, Urso M, Zambraski E, and Jacobson KA (2010) Adenosine A$_3$ receptors in muscle protection, in *A$_3$ Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics* (Borea PA, ed) pp 257–280, Springer, New York.

Linden J (1994) Cloned adenosine A$_3$ receptors: pharmacological properties, species differences and receptor functions. *Trends Pharmacol Sci* 15:298–306.

Linden J, Taylor HE, Robeva AS, Tucker AL, Stehle JH, Rivkees SA, Fink JS, and Reppert SM (1993) Molecular cloning and functional expression of a sheep A$_3$ adenosine receptor with widespread tissue distribution. *Mol Pharmacol* 44: 524–532.

Liu Y, Ytrehus K, and Downey JM (1994) Evidence that translocation of protein kinase C is a key event during ischemic preconditioning of rabbit myocardium. *J Mol Cell Cardiol* 26:661–668.

Lopes LV, Rebola N, Pinheiro PC, Richardson PJ, Oliveira CR, and Cunha RA (2003) Adenosine A$_3$ receptors are located in neurons of the rat hippocampus. *Neuroreport* 14:1645–1648.

Lu J, Pierron A, and Ravid K (2003) An adenosine analogue, IB-MECA, down-regulates estrogen receptor alpha and suppresses human breast cancer cell proliferation. *Cancer Res* 63:6413–6423.

Mabley J, Soriano F, Pacher P, Haskó G, Marton A, Wallace R, Salzman A, and Szabó C (2003) The adenosine A$_3$ receptor agonist, N^6-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. *Eur J Pharmacol* 466:323–329.

Macek TA, Schaffhauser H, and Conn PJ (1998) Protein kinase C and A$_3$ adenosine receptor activation inhibit presynaptic metabotropic glutamate receptor (mGluR) function and uncouple mGluRs from GTP-binding proteins. *J Neurosci* 18: 6138–6146.

Maconi A, Pastorin G, Da Ros T, Spalluto G, Gao ZG, Jacobson KA, Baraldi PG, Cacciari B, Varani K, and Moro S, et al. (2002) Synthesis, biological properties, and molecular modeling investigation of the first potent, selective, and water-soluble human A$_3$ adenosine receptor antagonist. *J Med Chem* 45:3579–3582.

Maddock HL, Mocanu MM, and Yellon DM (2002) Adenosine A(3) receptor activation protects the myocardium from reperfusion/reoxygenation injury. *Am J Physiol Heart Circ Physiol* 283:H1307–H1313.

Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, and Fishman P (2003) A$_3$ adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. *J Biol Chem* 278:42121–42130.

Madi L, Cohen S, Ochayin A, Bar-Yehuda S, Barer F, and Fishman P (2007) Overexpression of A$_3$ adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level. *J Rheumatol* 34:20–26.

Madi L, Ochaion A, Rath-Wolfson L, Bar-Yehuda S, Erlanger A, Ohana G, Harish A, Merimski O, Barer F, and Fishman P (2004) The A$_3$ adenosine receptor is highly expressed in tumor versus normal cells: potential target for tumor growth inhibition. *Clin Cancer Res* 10:4472–4479.

Madi L, Rosenberg-Haggen B, Nyska A, and Korenstein R (2013) Enhancing pigmentation via activation of A$_3$ adenosine receptors in B16 melanoma cells and in human skin explants. *Exp Dermatol* 22:74–77.

Martin L, Pingle SC, Hallam DM, Rybak LP, and Ramkumar V (2006) Activation of the adenosine A$_3$ receptor in RAW 264.7 cells inhibits lipopolysaccharide-stimulated tumor necrosis factor-alpha release by reducing calcium-dependent activation of nuclear factor-kappaB and extracellular signal-regulated kinase 1/2. *J Pharmacol Exp Ther* 316:71–78.

Matot I, Weiniger CF, Zeira E, Galun E, Joshi BV, and Jacobson KA (2006) A$_3$ adenosine receptors and mitogen-activated protein kinases in lung injury following in vivo reperfusion. *Crit Care* 10:R65.

McIntosh VJ and Lasley RD (2012) Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? *J Cardiovasc Pharmacol Ther* 17:21–33.

McWhinney CD, Dudley MW, Bowlin TL, Peet NP, Schook L, Bradshaw M, De M, Borcherding DR, and Edwards CK 3rd (1996) Activation of adenosine A$_3$ receptors on macrophages inhibits tumor necrosis factor-α. *Eur J Pharmacol* 310:209–216.

Melillo G (2004) HIF-1: a target for cancer, ischemia and inflammation—too good to be true? *Cell Cycle* 3:154–155.

Melman A, Gao ZG, Kumar D, Wan TC, Gizewski E, Auchampach JA, and Jacobson KA (2008) Design of (N)-methanocarba adenosine 5′-uronamides as species-independent A$_3$ receptor-selective agonists. *Bioorg Med Chem Lett* 18:2813–2819.

Menjoge AR, Kannan RM, and Tomalia DA (2010) Dendrimer-based drug and imaging conjugates: design considerations for nanomedical applications. *Drug Discov Today* 15:171–185.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, MacLennan S, Baraldi PG, and Borea PA (2005a) A$_3$ adenosine receptors modulate hypoxia-inducible factor-1alpha expression in human A375 melanoma cells. *Neoplasia* 7: 894–903.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, Baraldi PG, and Borea PA (2007a) Hypoxia inhibits paclitaxel-induced apoptosis through adenosine-mediated phosphorylation of bad in glioblastoma cells. *Mol Pharmacol* 72:162–172.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, and Borea PA (2005b) A$_3$ adenosine receptor activation inhibits cell proliferation via phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. *J Biol Chem* 280:19516–19526.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S, and Borea PA (2006) Adenosine modulates vascular endothelial growth factor expression via hypoxia-inducible factor-1 in human glioblastoma cells. *Biochem Pharmacol* 72:19–31.

Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E, Maclennan S, Baraldi PG, and Borea PA (2007b) Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells. *Mol Pharmacol* 72:395–406.

Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E, Baraldi PG, and Borea PA (2002a) Adenosine receptors as mediators of both cell proliferation and cell death of cultured human melanoma cells. *J Invest Dermatol* 119:923–933.

Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA, and Borea PA (2003) A glance at adenosine receptors: novel target for antitumor therapy. *Pharmacol Ther* 100:31–48.

Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, Baraldi PG, and Borea PA (2009) A$_{(2B)}$ and A$_{(3)}$ adenosine receptors modulate vascular endothelial growth factor and interleukin-8 expression in human melanoma cells treated with etoposide and doxorubicin. *Neoplasia* 11:1064–1073.

Merighi S, Simioni C, Lane R, and IJzerman AP (2010) Regulation of second messenger systems and intracellular pathways, in *A$_3$ Adenosine Receptors from Cell Biology to Pharmacology and Therapeutics* (Borea PA, ed) pp 257–280, Springer, New York.

Merighi S, Varani K, Gessi S, Cattabriga E, Iannotta V, Ulouglu C, Leung E, and Borea PA (2001) Pharmacological and biochemical characterization of adenosine receptors in the human malignant melanoma A375 cell line. *Br J Pharmacol* 134:1215–1226.

Merighi S, Varani K, Gessi S, Klotz K-N, Leung E, Baraldi PG, and Borea PA (2002b) Binding thermodynamics at the human A$_3$ adenosine receptor. *Biochem Pharmacol* **63**:157–161.

Meyerhof W, Müller-Brechlin R, and Richter D (1991) Molecular cloning of a novel putative G-protein coupled receptor expressed during rat spermiogenesis. *FEBS Lett* **284**:155–160.

Mitchell CH, Peterson-Yantorno K, Carré DA, McGlinn AM, Coca-Prados M, Stone RA, and Civan MM (1999) A$_3$ adenosine receptors regulate Cl$^-$ channels of non-pigmented ciliary epithelial cells. *Am J Physiol* **276**:C659–C666.

Montinaro A, Forte G, Sorrentino R, Luciano A, Palma G, Arra C, Adcock IM, Pinto A, and Morello S (2012) Adoptive immunotherapy with Cl-IB-MECA-treated CD8+ T cells reduces melanoma growth in mice. *PLoS ONE* **7**:e45401.

Morello S, Sorrentino R, Porta A, Forte G, Popolo A, Petrella A, and Pinto A (2009) Cl-IB-MECA enhances TRAIL-induced apoptosis via the modulation of NF-kappaB signalling pathway in thyroid cancer cells. *J Cell Physiol* **221**:378–386.

Morschl E, Molina JG, Volmer JB, Mohsenin A, Pero RS, Hong JS, Kheradmand F, Lee JJ, and Blackburn MR (2008) A$_3$ adenosine receptor signaling influences pulmonary inflammation and fibrosis. *Am J Respir Cell Mol Biol* **39**:697–705.

Mozzicato S, Joshi BV, Jacobson KA, and Liang BT (2004) Role of direct RhoA-phospholipase D1 interaction in mediating adenosine-induced protection from cardiac ischemia. *FASEB J* **18**:406–408.

Müller CE, Thorand M, Qurishi R, Diekmann M, Jacobson KA, Padgett WL, and Daly JW (2002) Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A$_{2A}$- and A$_3$-adenosine receptor antagonists. *J Med Chem* **45**:3440–3450.

Mulloy DP, Sharma AK, Fernandez LG, Zhao Y, Lau CL, Kron IL, and Laubach VE (2013) Adenosine A$_3$ receptor activation attenuates lung ischemia-reperfusion injury. *Ann Thorac Surg* **95**:1762–1767.

Murrison EM, Goodson SJ, Edbrooke MR, and Harris CA (1996) Cloning and characterisation of the human adenosine A$_3$ receptor gene. *FEBS Lett* **384**:243–246.

Nagaya H, Gotoh A, Kanno T, and Nishizaki T (2013) A$_3$ adenosine receptor mediates apoptosis in in vitro RCC4-VHL human renal cancer cells by up-regulating AMID expression. *J Urol* **189**:321–328.

Nakamura K, Yoshikawa N, Yamaguchi Y, Kagota S, Shinozuka K, and Kunitomo M (2006) Antitumor effect of cordycepin (3′-deoxyadenosine) on mouse melanoma and lung carcinoma cells involves adenosine A$_3$ receptor stimulation. *Anticancer Res* **26** (1A):43–47.

Nayak A, Chandra G, Hwang I, Kim K, Hou X, Kim HO, Sahu PK, Roy KK, Yoo J, and Lee Y, et al. (2014) Synthesis and anti-renal fibrosis activity of conformationally locked truncated 2-hexynyl-N(6)-substituted-(N)-methanocarba-nucleosides as A$_3$ adenosine receptor antagonists and partial agonists. *J Med Chem* **57**:1344–1354.

Neary JT, McCarthy M, Kang Y, and Zuniga S (1998) Mitogenic signaling from P1 and P2 purinergic receptors to mitogen-activated protein kinase in human fetal astrocyte cultures. *Neurosci Lett* **242**:159–162.

Nishat S, Shabir H, Azmi AS, and Ansari HR (2012) A$_3$ adenosine receptor: a plausible therapeutic target for cardio-protection in diabetes. *Recent Patents Cardiovasc Drug Discov* **7**:59–70.

Nogi Y, Kanno T, Nakano T, Fujita Y, Tabata C, Fukuoka K, Gotoh A, and Nishizaki T (2012) AMP converted from intracellularly transported adenosine upregulates p53 expression to induce malignant pleural mesothelioma cell apoptosis. *Cell Physiol Biochem* **30**:61–74.

Ochaion A, Bar-Yehuda S, Cohen S, Amital H, Jacobson KA, Joshi BV, Gao ZG, Barer F, Patoka R, and Del Valle L, et al. (2008) The A$_3$ adenosine receptor agonist CF502 inhibits the PI3K, PKB/Akt and NF-kappaB signaling pathway in synoviocytes from rheumatoid arthritis patients and in adjuvant-induced arthritis rats. *Biochem Pharmacol* **76**:482–494.

Ochaion A, Bar-Yehuda S, Cohen S, Barer F, Patoka R, Amital H, Reitblat T, Reitblat A, Ophir J, and Konfino I, et al. (2009) The anti-inflammatory target A$_3$ adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. *Cell Immunol* **258**:115–122.

Ohsawa K, Sanagi T, Nakamura Y, Suzuki E, Inoue K, and Kohsaka S (2012) Adenosine A$_3$ receptor is involved in ADP-induced microglial process extension and migration. *J Neurochem* **121**:217–227.

Okamura T, Kurogi Y, Nishikawa H, Hashimoto K, Fujiwara H, and Nagao Y (2002) 1,2,4-Triazolo[5,1-i]purine derivatives as highly potent and selective human adenosine A$_3$ receptor ligands. *J Med Chem* **45**:3703–3708.

Olah ME, Gallo-Rodriguez C, Jacobson KA, and Stiles GL (1994) [^{125}I]AB-MECA, a high affinity radioligand for the rat A$_3$ adenosine receptor. *Mol Pharmacol* **45**:978–982.

Ongaro A, Varani K, Masieri FF, Pellati A, Massari L, Cadossi R, Vincenzi F, Borea PA, Fini M, and Caruso A, et al. (2012) Electromagnetic fields (EMFs) and adenosine receptors modulate prostaglandin E(2) and cytokine release in human osteoarthritic synovial fibroblasts. *J Cell Physiol* **227**:2461–2469.

Otsuki T, Kanno T, Fujita Y, Tabata C, Fukuoka K, Nakano T, Gotoh A, and Nishizaki T (2012) A$_3$ adenosine receptor-mediated p53-dependent apoptosis in Lu-65 human lung cancer cells. *Cell Physiol Biochem* **30**:210–220.

Ozola V, Thorand M, Diekmann M, Qurishi R, Schumacher B, Jacobson KA, and Müller CE (2003) 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at Human A$_3$ adenosine receptors. *Bioorg Med Chem* **11**:347–356.

Palmer TM, Benovic JL, and Stiles GL (1995) Agonist-dependent phosphorylation and desensitization of the rat A$_3$ adenosine receptor. Evidence for a G-protein-coupled receptor kinase-mediated mechanism. *J Biol Chem* **270**:29607–29613.

Palmer TM and Stiles GL (2000) Identification of threonine residues controlling the agonist-dependent phosphorylation and desensitization of the rat A$_3$ adenosine receptor. *Mol Pharmacol* **57**:539–545.

Panjehpour M and Karami-Tehrani F (2004) An adenosine analog (IB-MECA) inhibits anchorage-dependent cell growth of various human breast cancer cell lines. *Int J Biochem Cell Biol* **36**:1502–1509.

Panther E, Idzko M, Herouy Y, Rheinen H, Gebicke-Haerter PJ, Mrowietz U, Dichmann S, and Norgauer J (2001) Expression and function of adenosine receptors in human dendritic cells. *FASEB J* **15**:1963–1970.

Paoletta S, Tosh DK, Finley A, Gizewski ET, Moss SM, Gao ZG, Auchampach JA, Salvemini D, and Jacobson KA (2013) Rational design of sulfonated A$_3$ adenosine receptor-selective nucleosides as pharmacological tools to study chronic neuropathic pain. *J Med Chem* **56**:5949–5963.

Peart JN and Headrick JP (2007) Adenosinergic cardioprotection: multiple receptors, multiple pathways. *Pharmacol Ther* **114**:208–221.

Pugliese AM, Coppi E, Volpini R, Cristalli G, Corradetti R, Jeong LS, Jacobson KA, and Pedata F (2007) Role of adenosine A$_3$ receptors on CA1 hippocampal neurotransmission during oxygen-glucose deprivation episodes of different duration. *Biochem Pharmacol* **74**:768–779.

Pugliese AM, Latini S, Corradetti R, and Pedata F (2003) Brief, repeated, oxygen-glucose deprivation episodes protect neurotransmission from a longer ischemic episode in the in vitro hippocampus: role of adenosine receptors. *Br J Pharmacol* **140**:305–314.

Ralevic V and Burnstock G (1998) Receptors for purines and pyrimidines. *Pharmacol Rev* **50**:413–492.

Ramkumar V, Stiles GL, Beaven MA, and Ali H (1993) The A$_3$ adenosine receptor is the unique adenosine receptor which facilitates release of allergic mediators in mast cells. *J Biol Chem* **268**:16887–16890.

Raskovalova T, Huang X, Sitkovsky M, Zacharia LC, Jackson EK, and Gorelik E (2005) Gs protein-coupled adenosine receptor signaling and lytic function of activated NK cells. *J Immunol* **175**:4383–4391.

Rasmussen SG, DeVree BT, Zou Y, Kruse AC, Chung KY, Kobilka TS, Thian FS, Chae PS, Pardon E, and Calinski D, et al. (2011) Crystal structure of the β2 adrenergic receptor-Gs protein complex. *Nature* **477**:549–555.

Rath-Wolfson L, Bar-Yehuda S, Madi L, Ochaion A, Cohen S, Zabutti A, and Fishman P (2006) IB-MECA, an A$_3$ adenosine receptor agonist prevents bone resorption in rats with adjuvant induced arthritis. *Clin Exp Rheumatol* **24**:400–406.

Rebola N, Rodrigues RJ, Oliveira CR, and Cunha RA (2005) Different roles of adenosine A1, A2A and A3 receptors in controlling kainate-induced toxicity in cortical cultured neurons. *Neurochem Int* **47**:317–325.

Reeves JJ, Harris CA, Hayes BP, Butchers PR, and Sheehan MJ (2000) Studies on the effects of adenosine A$_3$ receptor stimulation on human eosinophils isolated from non-asthmatic or asthmatic donors. *Inflamm Res* **49**:666–672.

Reeves JJ, Jones CA, Sheehan MJ, Vardey CJ, and Whelan CJ (1997) Adenosine A$_3$ receptors promote degranulation of rat mast cells both in vitro and in vivo. *Inflamm Res* **46**:180–184.

Reiss AB and Cronstein BN (2012) Regulation of foam cells by adenosine. *Arterioscler Thromb Vasc Biol* **32**:879–886.

Ren T, Grants I, Alhaj M, McKiernan M, Jacobson M, Hassanain HH, Frankel W, Wunderlich J, and Christofi FL (2011) Impact of disrupting adenosine A$_3$ receptors (A$_3$$^{-/-}$AR) on colonic motility or progression of colitis in the mouse. *Inflamm Bowel Dis* **17**:1698–1713.

Reshkin SJ, Guerra L, Bagorda A, Debellis L, Cardone R, Li AH, Jacobson KA, and Casavola V (2000) Activation of A$_3$ adenosine receptor induces calcium entry and chloride secretion in A(6) cells. *J Membr Biol* **178**:103–113.

Ribeiro JA and Sebastião AM (1984) Enhancement of tetrodotoxin-induced axonal blockade by adenosine, adenosine analogues, dibutyryl cyclic AMP and methylxanthines in the frog sciatic nerve. *Br J Pharmacol* **83**:485–492.

Ribeiro JA and Sebastião AM (1986) Adenosine receptors and calcium: basis for proposing a third (A$_3$) adenosine receptor. *Prog Neurobiol* **26**:179–209.

Rivera-Oliver M and Díaz-Ríos M (2014) Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. *Life Sci* **101**:1–9.

Rivkees SA (1994) Localization and characterization of adenosine receptor expression in rat testis. *Endocrinology* **135**:2307–2313.

Rivkees SA, Thevananther S, and Hao H (2000) Are A$_3$ adenosine receptors expressed in the brain? *Neuroreport* **11**:1025–1030.

Roseti C, Palma E, Martinello K, Fucile S, Morace R, Esposito V, Cantore G, Arcella A, Giangaspero F, and Aronica E, et al. (2009) Blockage of A$_{2A}$ and A$_3$ adenosine receptors decreases the desensitization of human GABA$_{A}$ receptors microtransplanted to Xenopus oocytes. *Proc Natl Acad Sci USA* **106**:15927–15931.

Ryzhov S, Goldstein AE, Matafonov A, Zeng D, Biaggioni I, and Feoktistov I (2004) Adenosine-activated mast cells induce IgE synthesis by B lymphocytes: an A$_{2B}$-mediated process involving Th2 cytokines IL-4 and IL-13 with implications for asthma. *J Immunol* **172**:7726–7733.

Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, and Firestein GS (1996) Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. *J Immunol* **156**:3435–3442.

Saki M, Tsumuki H, Nonaka H, Shimada J, and Ichimura M (2002) KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A$_3$ receptor antagonist. *Eur J Pharmacol* **444**:133–141.

Sakowicz-Burkiewicz M, Kitowska A, Grden M, Maciejewska I, Szutowicz A, and Pawelczyk T (2013) Differential effect of adenosine receptors on growth of human colon cancer HCT 116 and HT-29 cell lines. *Arch Biochem Biophys* **533**:47–54.

Salie R, Moolman JA, and Lochner A (2012) The mechanism of beta-adrenergic preconditioning: roles for adenosine and ROS during triggering and mediation. *Basic Res Cardiol* **107**:281.

Salvatore CA, Jacobson MA, Taylor HE, Linden J, and Johnson RG (1993) Molecular cloning and characterization of the human A$_3$ adenosine receptor. *Proc Natl Acad Sci USA* **90**:10365–10369.

Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, and Jacobson MA (2000) Disruption of the A$_3$ adenosine receptor gene in mice and its effect on stimulated inflammatory cells. *J Biol Chem* **275**:4429–4434.

Sandhu H, Cooper S, Eckert M, Pisula L, Chinweike C, Gharanei M, and Maddock HL (2014) Cardioprotection during chemotherapy: a case study to understand intracellular mechanisms to combat the cardiotoxicity of sunitinib. *Heart* **100**:A7–A8.

Sattin A and Rall TW (1970) The effect of adenosine and adenine nucleotides on the cyclic adenosine 3′, 5′-phosphate content of guinea pig cerebral cortex slices. *Mol Pharmacol* **6**:13–23.

Sawynok J, Zarrindast MR, Reid AR, and Doak GJ (1997) Adenosine A3 receptor activation produces nociceptive behaviour and edema by release of histamine and 5-hydroxytryptamine. *Eur J Pharmacol* **333**:1–7.

Schlötzer-Schrehardt U, Zenkel M, Decking U, Haubs D, Kruse FE, Jünemann A, Coca-Prados M, and Naumann GO (2005) Selective upregulation of the A₃ adenosine receptor in eyes with pseudoexfoliation syndrome and glaucoma. *Invest Ophthalmol Vis Sci* **46**:2023–2034.

Schulte G and Fredholm BB (2000) Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. *Mol Pharmacol* **58**:477–482.

Schulte G and Fredholm BB (2002) Signaling pathway from the human adenosine A(3) receptor expressed in Chinese hamster ovary cells to the extracellular signal-regulated kinase 1/2. *Mol Pharmacol* **62**:1137–1146.

Sebastiao AM, Ribeiro FF, and Ribeiro JA (2012) From A₁ to A₃ en passant through A(2A) receptors in the hippocampus: pharmacological implications. *CNS Neurol Disord Drug Targets* **11**:652–663.

Sei Y, Von Lubitz DKJE, Abbracchio MP, Ji X-D, and Jacobson KA (1997) Adenosine A₃ receptor agonist-induced neurotoxicity in rat cerebellar granule neurons. *Drug Dev Res* **40**:267–273.

Shepherd RK, Linden J, and Duling BR (1996) Adenosine-induced vasoconstriction in vivo. Role of the mast cell and A3 adenosine receptor. *Circ Res* **78**:627–634.

Shneyvays V, Leshem D, Zinman T, Mamedova LK, Jacobson KA, and Shainberg A (2005) Role of adenosine A₁ and A₃ receptors in regulation of cardiomyocyte homeostasis after mitochondrial respiratory chain injury. *Am J Physiol Heart Circ Physiol* **288**:H2792–H2801.

Shneyvays V, Mamedova L, Zinman T, Jacobson K, and Shainberg A (2001) Activation of A(3)adenosine receptor protects against doxorubicin-induced cardiotoxicity. *J Mol Cell Cardiol* **33**:1249–1261.

Shneyvays V, Nawrath H, Jacobson KA, and Shainberg A (1998) Induction of apoptosis in cardiac myocytes by an A₃ adenosine receptor agonist. *Exp Cell Res* **243**:383–397.

Shneyvays V, Zinman T, and Shainberg A (2004) Analysis of calcium responses mediated by the A₃ adenosine receptor in cultured newborn rat cardiac myocytes. *Cell Calcium* **36**:387–396.

Siddiqi SM, Jacobson KA, Esker JL, Olah ME, Ji XD, Melman N, Tiwari KN, Secrist JA 3rd, Schneller SW, and Cristalli G, et al. (1995) Search for new purine- and ribose-modified adenosine analogues as selective agonists and antagonists at adenosine receptors. *J Med Chem* **38**:1174–1188.

Silverman MH, Strand V, Markovits D, Nahir M, Reitblat T, Molad Y, Rosner I, Rozenbaum M, Mader R, and Adawi M, et al. (2008) Clinical evidence for utilization of the A₃ adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial. *J Rheumatol* **35**:41–48.

Smith SR, Denhardt G, and Terminelli C (2002) A role for histamine in cytokine modulation by the adenosine A(3) receptor agonist, 2-Cl-IB-MECA. *Eur J Pharmacol* **457**:57–69.

Soares AS, Costa VM, Diniz C, and Fresco P (2014) Combination of Cl-IB-MECA with paclitaxel is a highly effective cytotoxic therapy causing mTOR-dependent autophagy and mitotic catastrophe on human melanoma cells. *J Cancer Res Clin Oncol* **140**:921–935.

Spicuzza L, Di Maria G, and Polosa R (2006) Adenosine in the airways: implications and applications. *Eur J Pharmacol* **533**:77–88.

Stamp LK, Hazlett J, Roberts RL, Frampton C, Highton J, and Hessian PA (2012) Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action. *Arthritis Res Ther* **14**:R138.

Stemmer SM, Benjaminov O, Medalia G, Ciuraru NB, Silverman MH, Bar-Yehuda S, Fishman S, Harpaz Z, Farbstein M, and Cohen S, et al. (2013) CF102 for the treatment of hepatocellular carcinoma: a phase I/II, open-label, dose-escalation study. *Oncologist* **18**:25–26.

Stoddart LA, Kellam B, Briddon SJ, and Hill SJ (2014) Effect of a toggle switch mutation in TM6 of the human adenosine A₃ receptor on Gi protein-dependent signalling and Gi-independent receptor internalization. *Br J Pharmacol* **171**:3827–3844.

Suh BC, Kim TD, Lee JU, Seong JK, and Kim KT (2001) Pharmacological characterization of adenosine receptors in PGT-beta mouse pineal gland tumour cells. *Br J Pharmacol* **134**:132–142.

Szabó C, Scott GS, Virág L, Egnaczyk G, Salzman AL, Shanley TP, and Haskó G (1998) Suppression of macrophage inflammatory protein (MIP)-1alpha production and collagen-induced arthritis by adenosine receptor agonists. *Br J Pharmacol* **125**:379–387.

Taliani S, La Motta C, Mugnaini L, Simorini F, Salerno S, Marini AM, Da Settimo F, Cosconati S, Cosimelli B, and Greco G, et al. (2010) Novel N2-substituted pyrazolo [3,4-d]pyrimidine adenosine A₃ receptor antagonists: inhibition of A₃-mediated human glioblastoma cell proliferation. *J Med Chem* **53**:3954–3963.

Talukder MA, Morrison RR, Jacobson MA, Jacobson KA, Ledent C, and Mustafa SJ (2002) Targeted deletion of adenosine A(3) receptors augments adenosine-induced coronary flow in isolated mouse heart. *Am J Physiol Heart Circ Physiol* **282**:H2183–H2189.

Tchilibon S, Joshi BV, Kim SK, Duong HT, Gao ZG, and Jacobson KA (2005) (N)-methanocarba 2,N6-disubstituted adenine nucleosides as highly potent and selective A₃ adenosine receptor agonists. *J Med Chem* **48**:1745–1758.

Teng B, Fil D, Tilley SL, Ledent C, Krahn T, and Mustafa SJ (2013) Functional and RNA expression profile of adenosine receptor subtypes in mouse mesenteric arteries. *J Cardiovasc Pharmacol* **61**:70–76.

Thiele A, Kronstein R, Wetzel A, Gerth A, Nieber K, and Hauschildt S (2004) Regulation of adenosine receptor subtypes during cultivation of human monocytes: role of receptors in preventing lipopolysaccharide-triggered respiratory burst. *Infect Immun* **72**:1349–1357.

Thourani VH, Nakamura M, Ronson RS, Jordan JE, Zhao Z-Q, Levy JH, Szlam F, Guyton RA, and Vinten-Johansen J (1999a) Adenosine A(3)-receptor stimulation attenuates postischemic dysfunction through K(ATP) channels. *Am J Physiol* **277**: H228–H235.

Thourani VH, Ronson RS, Jordan JE, Guyton RA, and Vinten-Johansen J (1999b) Adenosine A₃ pretreatment before cardioplegic arrest attenuates postischemic cardiac dysfunction. *Ann Thorac Surg* **67**:1732–1737.

Tilley SL, Tsai M, Williams CM, Wang ZS, Erikson CJ, Galli SJ, and Koller BH (2003) Identification of A₃ receptor- and mast cell-dependent and -independent components of adenosine-mediated airway responsiveness in mice. *J Immunol* **171**: 331–337.

Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, and Koller BH (2000) Adenosine and inosine increase cutaneous vasopermeability by activating A(3) receptors on mast cells. *J Clin Invest* **105**:361–367.

Tosh DK, Yoo LS, Chinn M, Hong K, Kilbey SM 2nd, Barrett MO, Fricks IP, Harden TK, Gao ZG, and Jacobson KA (2010) Polyamidoamine (PAMAM) dendrimer conjugates of "clickable" agonists of the A₃ adenosine receptor and coactivation of the P2Y14 receptor by a tethered nucleotide. *Bioconjug Chem* **21**:372–384.

Tracey WR, Magee W, Masamune H, Kennedy SP, Knight DR, Buchholz RA, and Hill RJ (1997) Selective adenosine A₃ receptor stimulation reduces ischemic myocardial injury in the rabbit heart. *Cardiovasc Res* **33**:410–415.

Tracey WR, Magee W, Masamune H, Oleynek JJ, and Hill RJ (1998) Selective activation of adenosine A3 receptors with N6-(3-chlorobenzyl)-5′-N-methylcarboxamidoadenosine (CB-MECA) provides cardioprotection via KATP channel activation. *Cardiovasc Res* **40**: 138–145.

Trincavelli ML, Tuscano D, Marroni M, Falleni A, Gremigni V, Ceruti S, Abbracchio MP, Jacobson KA, Cattabeni F, and Martini C (2002a) A₃ adenosine receptors in human astrocytoma cells: agonist-mediated desensitization, internalization, and down-regulation. *Mol Pharmacol* **62**:1373–1384.

Trincavelli ML, Tuscano D, Marroni M, Klotz KN, Lucacchini A, and Martini C (2002b) Involvement of mitogen protein kinase cascade in agonist-mediated human A(3) adenosine receptor regulation. *Biochim Biophys Acta* **1591**:55–62.

Tsuchida T, Kato T, Yamaga M, Ikebe K, Oniki Y, Irie H, and Takagi K (2003) The effect of perfusion with UW solution on the skeletal muscle and vascular endothelial exocrine function in rat hindlimbs. *J Surg Res* **110**:266–271.

Urso ML, Wang R, Zambraski EJ, and Liang BT (2012) Adenosine A3 receptor stimulation reduces muscle injury following physical trauma and is associated with alterations in the MMP/TIMP response. *J Appl Physiol (1985)* **112**:658–670.

van der Hoeven D, Wan TC, and Auchampach JA (2008) Activation of the A(3) adenosine receptor suppresses superoxide production and chemotaxis of mouse bone marrow neutrophils. *Mol Pharmacol* **74**:685–696.

van der Putten C, Zuiderwijk-Sick EA, van Straalen L, de Geus ED, Boven LA, Kondova I, IJzerman AP, and Bajramovic JJ (2009) Differential expression of adenosine A₃ receptors controls adenosine A(2A) receptor-mediated inhibition of TLR responses in microglia. *J Immunol* **182**:7603–7612.

van Muijlwijk-Koezen JE, Timmerman H, van der Goot H, Menge WM, Frijtag Von Drabbe Künzel J, de Groote M, IJzerman AP, and IJzerman AP (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A(3) receptor. *J Med Chem* **43**:2227–2238.

van Troostenburg AR, Clark EV, Carey WD, Warrington SJ, Kerns WD, Cohn I, Silverman MH, Bar-Yehuda S, Fong KL, and Fishman P (2004) Tolerability, pharmacokinetics and concentration-dependent hemodynamic effects of oral CF101, an A₃ adenosine receptor agonist, in healthy young men. *Int J Clin Pharmacol Ther* **42**:534–542.

Varani K, Caramori G, Vincenzi F, Adcock I, Casolari P, Leung E, Maclennan S, Gessi S, Morello S, and Barnes PJ, et al. (2006) Alteration of adenosine receptors in patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* **173**:398–406.

Varani K, Caramori G, Vincenzi F, Tosi A, Barczyk A, Contoli M, Casolari P, Triggiani M, Hansel T, and Leung E, et al. (2010) Oxidative/nitrosative stress selectively altered A(2B) adenosine receptors in chronic obstructive pulmonary disease. *FASEB J* **24**:1192–1204.

Varani K, De Mattei M, Vincenzi F, Gessi S, Merighi S, Pellati A, Ongaro A, Caruso A, Cadossi R, and Borea PA (2008) Characterization of adenosine receptors in bovine chondrocytes and fibroblast-like synoviocytes exposed to low frequency low energy pulsed electromagnetic fields. *Osteoarthritis Cartilage* **16**:292–304.

Varani K, Maniero S, Vincenzi F, Targa M, Stefanelli A, Maniscalco P, Martini F, Tognon M, and Borea PA (2011a) A₃ receptors are overexpressed in pleura from patients with mesothelioma and reduce cell growth via Akt/nuclear factor-κB pathway. *Am J Respir Crit Care Med* **183**:522–530.

Varani K, Massara A, Vincenzi F, Tosi A, Padovan M, Trotta F, and Borea PA (2009) Normalization of A(2A) and A₃ adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. *Arthritis Rheum* **60**:2880–2891.

Varani K, Merighi S, Gessi S, Klotz KN, Leung E, Baraldi PG, Cacciari B, Romagnoli R, Spalluto G, and Borea PA (2000) [(3)H]MRE 3008F20: a novel antagonist radioligand for the pharmacological and biochemical characterization of human A(3) adenosine receptors. *Mol Pharmacol* **57**:968–975.

Varani K, Padovan M, Govoni M, Vincenzi F, Trotta F, and Borea PA (2010a) The role of adenosine receptors in rheumatoid arthritis. *Autoimmun Rev* **10**:61–64.

Varani K, Padovan M, Vincenzi F, Targa M, Trotta F, Govoni M, and Borea PA (2011b) A(2A) and A₃ adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release. *Arthritis Res Ther* **13**:R197.

Varani K, Vincenzi F, Tosi A, Gessi S, Casetta I, Granieri G, Fazio P, Leung E, MacLennan S, and Granieri E, et al. (2010b) A(2A) adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease. *FASEB J* **24**:587–598.

Varani K, Vincenzi F, Tosi A, Targa M, Masieri FF, Ongaro A, De Mattei M, Massari L, and Borea PA (2010c) Expression and functional role of adenosine receptors in

regulating inflammatory responses in human synoviocytes. *Br J Pharmacol* **160**: 101–115.

Varani K, Vincenzi F, Targa M, Paradiso B, Parrilli A, Fini M, Lanza G, and Borea PA (2013) The stimulation of A(3) adenosine receptors reduces bone-residing breast cancer in a rat preclinical model. *Eur J Cancer* **49**:482–491.

Velot E, Haas B, Léonard F, Ernens I, Rolland-Turner M, Schwartz C, Longrois D, Devaux Y, and Wagner DR (2008) Activation of the adenosine-A₃ receptor stimulates matrix metalloproteinase-9 secretion by macrophages. *Cardiovasc Res* **80**: 246–254.

Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Goldring MB, Borea PA, and Varani K (2013) Pulsed electromagnetic fields increased the anti-inflammatory effect of A₂A and A₃ adenosine receptors in human T/C-28a2 chondrocytes and hFOB 1.19 osteoblasts. *PLoS ONE* **8**:e65561.

Vincenzi F, Targa M, Corciulo C, Gessi S, Merighi S, Setti S, Cadossi R, Borea PA, and Varani K (2012) The anti-tumor effect of A₃ adenosine receptors is potentiated by pulsed electromagnetic fields in cultured neural cancer cells. *PLoS ONE* **7**: e39317.

Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, and Cristalli G (2002) N(6)-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A(3) receptor and a starting point for searching A(2B) ligands. *J Med Chem* **45**:3271–3279.

Volpini R, Buccioni M, Dal Ben D, Lambertucci C, Lammi C, Marucci G, Ramadori AT, Klotz KN, and Cristalli G (2009) Synthesis and biological evaluation of 2-alkynyl-N6-methyl-5′-N-methylcarboxamidoadenosine derivatives as potent and highly selective agonists for the human adenosine A₃ receptor. *J Med Chem* **52**: 7897–7900.

von Arnim CA, Verstege E, Etrich SM, and Riepe MW (2006) Mechanisms of hypoxic tolerance in presymptomatic APP23 transgenic mice. *Mech Ageing Dev* **127**:109–114.

von Lubitz DK (1999) Adenosine and cerebral ischemia: therapeutic future or death of a brave concept? *Eur J Pharmacol* **371**:85–102.

Von Lubitz DKJE, Lin RCS, Popik P, Carter MF, and Jacobson KA (1994) Adenosine A₃ receptor stimulation and cerebral ischemia. *Eur J Pharmacol* **263**:59–67.

Von Lubitz DKJE, Simpson KL, and Lin RCS (2001) Right thing at a wrong time? Adenosine A₃ receptors and cerebroprotection in stroke. *Ann N Y Acad Sci* **939**:85–96.

Wadsak W, Mien LK, Shanab K, Ettlinger DE, Haeusler D, Sindelar K, Lanzenberger RR, Spreitzer H, Viernstein H, and Keppler BK, et al. (2008) Preparation and first evaluation of [(18)F]FE@SUPPY: a new PET tracer for the adenosine A(3) receptor. *Nucl Med Biol* **35**:61–66.

Wan TC, Ge ZD, Tampo A, Mio Y, Bienengraeber MW, Tracey WR, Gross GJ, Kwok WM, and Auchampach JA (2008) The A₃ adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5′-N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. *J Pharmacol Exp Ther* **324**:234–243.

Wan TC, Tosh DK, Du L, Gizewski ET, Jacobson KA, and Auchampach JA (2011) Polyamidoamine (PAMAM) dendrimer conjugate specifically activates the A₃ adenosine receptor to improve post-ischemic/reperfusion function in isolated mouse hearts. *BMC Pharmacol* **11**:11.

Wang Z, Do CW, Avila MY, Peterson-Yantorno K, Stone RA, Gao ZG, Joshi B, Besada P, Jeong LS, and Jacobson KA, et al. (2010) Nucleoside-derived antagonists to A₃ adenosine receptors lower mouse intraocular pressure and act across species. *Exp Eye Res* **90**:146–154.

Wen LT and Knowles AF (2003) Extracellular ATP and adenosine induce cell apoptosis of human hepatoma Li-7A cells via the A₃ adenosine receptor. *Br J Pharmacol* **140**:1009–1018.

Wittendorp MC, Boddeke HW, and Biber K (2004) Adenosine A₃ receptor-induced CCL2 synthesis in cultured mouse astrocytes. *Glia* **46**:410–418.

Wu WP, Hao JX, Halldner-Henriksson L, Xu XJ, Jacobson MA, Wiesenfeld-Hallin Z, and Fredholm BB (2002) Decreased inflammatory pain due to reduced carrageenan-induced inflammation in mice lacking adenosine A3 receptors. *Neuroscience* **114**: 523–527.

Xu Z, Jang Y, Mueller RA, and Norfleet EA (2006) IB-MECA and cardioprotection. *Cardiovasc Drug Rev* **24**:227–238.

Yaar R, Lamperti ED, Toselli PA, and Ravid K (2002) Activity of the A₃ adenosine receptor gene promoter in transgenic mice: characterization of previously unidentified sites of expression. *FEBS Lett* **532**:267–272.

Yang H, Avila MY, Peterson-Yantorno K, Coca-Prados M, Stone RA, Jacobson KA, and Civan MM (2005) The cross-species A₃ adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure. *Curr Eye Res* **30**:747–754.

Yao Y, Sei Y, Abbracchio MP, Jiang JL, Kim YC, and Jacobson KA (1997) Adenosine A₃ receptor agonists protect HL-60 and U-937 cells from apoptosis induced by A₃ antagonists. *Biochem Biophys Res Commun* **232**:317–322.

Yoon MH, Bae HB, and Choi JI (2005) Antinociception of intrathecal adenosine receptor subtype agonists in rat formalin test. *Anesth Analg* **101**:1417–1421.

Young HW, Molina JG, Dimina D, Zhong H, Jacobson M, Chan LN, Chan TS, Lee JJ, and Blackburn MR (2004) A₃ adenosine receptor signaling contributes to airway inflammation and mucus production in adenosine deaminase-deficient mice. *J Immunol* **173**:1380–1389.

Zhai P, Sciarretta S, Galeotti J, Volpe M, and Sadoshima J (2011) Differential roles of GSK-3β during myocardial ischemia and ischemia/reperfusion. *Circ Res* **109**: 502–511.

Zhang M, Budak MT, Lu W, Khurana TS, Zhang X, Laties AM, and Mitchell CH (2006a) Identification of the A₃ adenosine receptor in rat retinal ganglion cells. *Mol Vis* **12**:937–948.

Zhang M, Hu H, Zhang X, Lu W, Lim J, Eysteinsson T, Jacobson KA, Laties AM, and Mitchell CH (2010) The A₃ adenosine receptor attenuates the calcium rise triggered by NMDA receptors in retinal ganglion cells. *Neurochem Int* **56**:35–41.

Zhang W, Moskowitz RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, and Doherty M, et al. (2008) OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. *Osteoarthritis Cartilage* **16**:137–162.

Zhang X, Zhang M, Laties AM, and Mitchell CH (2006b) Balance of purines may determine life or death of retinal ganglion cells as A₃ adenosine receptors prevent loss following P2X7 receptor stimulation. *J Neurochem* **98**:566–575.

Zhao TC and Kukreja RC (2002) Late preconditioning elicited by activation of adenosine A(3) receptor in heart: role of NF-kappa B, iNOS and mitochondrial K (ATP) channel. *J Mol Cell Cardiol* **34**:263–277.

Zhao TC and Kukreja RC (2003) Protein kinase C-delta mediates adenosine A₃ receptor-induced delayed cardioprotection in mouse. *Am J Physiol Heart Circ Physiol* **285**:H434–H441.

Zheng J, Wang R, Zambraski E, Wu D, Jacobson KA, and Liang BT (2007) Protective roles of adenosine A₁, A₂A, and A₃ receptors in skeletal muscle ischemia and reperfusion injury. *Am J Physiol Heart Circ Physiol* **293**:H3685–H3691.

Zhong H, Shlykov SG, Molina JG, Sanborn BM, Jacobson MA, Tilley SL, and Blackburn MR (2003) Activation of murine lung mast cells by the adenosine A₃ receptor. *J Immunol* **171**:338–345.

Zhou H, Chen F, Li Q, Hu DY, and Liu LM (2010) Stimulation of the adenosine A₃ receptor reverses vascular hyporeactivity after hemorrhagic shock in rats. *Acta Pharmacol Sin* **31**:413–420.

Zhou QY, Li C, Olah ME, Johnson RA, Stiles GL, and Civelli O (1992) Molecular cloning and characterization of an adenosine receptor: the A₃ adenosine receptor. *Proc Natl Acad Sci USA* **89**:7432–7436.

Zhu CB, Lindler KM, Campbell NG, Sutcliffe JS, Hewlett WA, and Blakely RD (2011) Colocalization and regulated physical association of presynaptic serotonin transporters with A₃ adenosine receptors. *Mol Pharmacol* **80**:458–465.

Zhu CB, Steiner JA, Munn JL, Daws LC, Hewlett WA, and Blakely RD (2007) Rapid stimulation of presynaptic serotonin transport by A(3) adenosine receptors. *J Pharmacol Exp Ther* **322**:332–340.

Zimmermann H (2000) Extracellular metabolism of ATP and other nucleotides. *Naunyn Schmiedebergs Arch Pharmacol* **362**:299–309.